Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2014

Multimodality Molecular Imaging of [18F]-Fluorinated Carboplatin
Derivative Encapsulated in [111In]-Labeled Liposome
Narottam Lamichhane
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Health and Medical Physics Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/3347

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

Multimodality Molecular Imaging of [18F]-Fluorinated Carboplatin
Derivative Encapsulated in [111In]-Labeled Liposomes
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Medical Physics at Virginia Commonwealth University

by

Narottam Lamichhane
Bachelor of Science in Applied Physics and Chemistry
Arcadia University, PA, 2009

Director: Jamal Zweit, PhD, DSc
Professor, Department of Radiology

Virginia Commonwealth University
Richmond, Virginia
March 21, 2014

Acknowledgements
This project was brought to fruition by teamwork and was benefited from inputs and
insights from several people. First and foremost, I would like to thank Dr. Jamal Zweit
for giving me an opportunity to work under his guidance. I am very fortunate to have him
as my advisor. I am indebted to his continuous enthusiasm, encouragement and relentless
support towards this project. His continuous guidance always pushed me to do well not
only in this project but also in everything I do.
Dr. Gajanan Dewkar contributed his inputs all the way through this research. I want to
acknowledge him for teaching me and showing me the real world of synthetic organic
chemistry. His motivation and help in radiosynthetic procedures is remarkable. My
special thanks go to Dr. Sundaresan Gobalakrishnan. Dr. Gobalakrishnan’s vision and
foresightedness swerved this project in many ways and made it a beautiful piece of
science. His unstinting way of dealing with problems always enticed me and guided me
throughout my graduate career. Dr. Minghao Sun’s help in the nanodrug delivery part of
this project is noteworthy. His generous help in various labeling and analysis procedures
made a huge impact in this project. I want to thank Dr. Purnima Jose for instructing me in
various molecular biological procedures and analysis. Ms. Li Wang helped me in
numerous biodistribution studies. I am greatly obliged to her availability and her
willingness to help me anytime. I am very thankful for all the administrative and
technical assistance that I have received from Ms. Chelsea Stine, Ms.Celina Thadigiri, Dr.
Likun Yang, and Dr. Vimalan Vijayaragavan during this project.
David Hoffman has been a wonderful companion and a best friend to me during my
graduate journey. I loved listening to his stories on history and about his past life. It has
been a wonderful experience working with Philip McDonagh. Either it’s listening to
Ke$ha or spending long after hours in lab, I have shared some wonderful memories with
him. I want to thank all my friends here at VCU for making this graduate journey, a
beautiful ride.
I want to thank my family back in Nepal for inspiring me to pursue my education abroad.
Without them, my journey would have never been complete. My appreciation goes to my
brother, Puru, for always reminding me about the best part of graduate career. I want to
extend my appreciation to all my committee members for being a part of this project and
a part of my graduate career.
Finally, I want to thank my girlfriend, Priyanka, for her undying love and for being a
constant source of inspiration to me.
I dedicate my dissertation to humanity.

ii

Table of Contents
Acknowledgements ............................................................................................................. ii
Table of Contents ............................................................................................................... iii
List of Tables ..................................................................................................................... vi
List of Figures ................................................................................................................... vii
List of Abbreviations ......................................................................................................... xi
Abstract ............................................................................................................................ xiv
CHAPTER 1: INTRODUCTION ................................................................................... - 1 1.1 Rationale........................................................................................................... - 2 1.2 Objective .......................................................................................................... - 2 1.3 Statement of Aims ............................................................................................ - 3 1.4 Innovation......................................................................................................... - 4 1.5 Impact ............................................................................................................... - 5 1.6 Research Strategy/ Experimental Design ......................................................... - 6 CHAPTER 2: BACKGROUND ..................................................................................... - 8 2.1 Cancer............................................................................................................... - 9 2.2 Solid Tumors and Cancer Biology ................................................................. - 12 2.3 Imaging in Cancer Care.................................................................................. - 14 2.4 Cancer Treatment and Therapy ...................................................................... - 15 2.4.1
Surgery .................................................................................................... - 16 2.4.2
Radiation Therapy................................................................................... - 17 2.4.3
Biologically Targeted Therapy ............................................................... - 19 2.4.4
Chemotherapy ......................................................................................... - 21 2.4.4.1 Platinum Therapy .................................................................................. - 23 2.4.4.2 Development of Platinum Analogues ................................................... - 27 2.4.4.3 Multidrug Resistance to Platinum ......................................................... - 29 References ................................................................................................................. - 33 CHAPTER 3: MOLECULAR IMAGING IN CANCER THERAPY .......................... - 36 3.1 Molecular Imaging in Cancer Therapy .......................................................... - 37 3.2 Radiotracer Imaging ....................................................................................... - 39 3.2.1 Single Photon Emission Tomography ......................................................... - 39 3.2.2
Positron Emission Tomography.............................................................. - 41 3.3 Molecular Imaging in Image Guided Therapy ............................................... - 45 3.3.1
Molecular Imaging in Staging and Tumor Expression ........................... - 46 3.3.2
Tumor Metabolism Imaging ................................................................... - 47 3.3.3
Tumor Proliferation Imaging .................................................................. - 50 3.3.4
Cell Death Imaging ................................................................................. - 53 References ................................................................................................................. - 56 CHAPTER 4: NANOPARTICLE DELIVERY OF ANTI-CANCER DRUGS ........... - 58 4.1 Drug Delivery Systems .................................................................................. - 59 4.2 Nanoparticles in Drug Delivery ..................................................................... - 60 4.3 Liposomes in Drug Delivery .......................................................................... - 62 References ................................................................................................................. - 69 CHAPTER 5: FLUORINATED CARBOPLATIN DERIVATIVE: A NOVEL
THERANOSTIC ANTICANCER DRUG FOR THERAPY AND IMAGING ........... - 71 5.1 Introduction .................................................................................................... - 72 -

iii

5.2 Experimental Section ..................................................................................... - 74 5.2.1
Materials ................................................................................................. - 74 5.2.2
Synthesis of Cold Reference (19F-FCP) .................................................. - 75 5.2.2.1 Diethyl 2-(5-bromopentyl)-2-methylmalonate (1) ................................ - 75 5.2.2.2 Diethyl 2-methyl-2-(5-(tosyloxy)pentyl)malonate (2) .......................... - 76 5.2.2.3 Diethyl 2-(5-fluoropentyl)-2-methylmalonate (3) ................................ - 76 5.2.2.4 2-(5-Fluoropentyl)-2-methylmalonic acid (4)....................................... - 77 5.2.2.5 Non-radioactive Reference Compound 19F-FCP .................................. - 78 5.2.3
Manual Synthesis and Characterization of [18F]-FCP ............................ - 78 5.2.4
Automated Synthesis and Characterization of [18F]-FCP ....................... - 79 5.2.5
Cell Lines and Culture Conditions .......................................................... - 81 5.2.6
Tumor Xenograft/Animal Model ............................................................ - 81 5.2.7
In vitro Cytotoxicity of 19F-FCP ............................................................. - 82 5.2.8
Biodistribution and in vivo Stability Analysis ........................................ - 83 5.2.9
PET Imaging Studies .............................................................................. - 84 5.2.10 Protein Extraction and Western Blot ...................................................... - 84 5.3 Results ............................................................................................................ - 85 5.3.1
Synthesis of 19F-FCP............................................................................... - 85 5.3.2
In vitro Cytotoxicity of 19F-FCP ............................................................. - 87 5.3.3
Radiosynthesis of [18F]-FCP ................................................................... - 88 5.3.4
Biodistribution and in vivo Stability Analysis ........................................ - 91 5.3.5
PET Imaging Studies .............................................................................. - 93 5.3.6
Protein expression and Western Blotting ................................................ - 95 5.4 Discussion ........................................................................................................... - 95 5.5 Conclusion .......................................................................................................... - 97 References ............................................................................................................... - 105 CHAPTER 6: LIPOSOMAL CARBOPLATIN: A NOVEL DOUBLE RADIOLABELED
NANOCONSTRUCT FOR DUAL TRACER IMAGING AND THERAPY ............ - 107 6.1 Introduction .................................................................................................. - 108 6.2 Experimental ................................................................................................ - 110 6.2.1
Chemicals .............................................................................................. - 110 6.2.2
[111In]-Labeled Liposome Preparation .................................................. - 111 6.2.3
Labeling Procedure ............................................................................... - 111 6.2.4
Biodistribution of [111In]-Labeled Liposome: ....................................... - 112 6.2.5
In vivo SPECT/CT Imaging of [111In]-Labeled Liposome ................... - 112 6.2.6
Synthesis of [18F]-FCP encapsulated [111In]-Labeled Liposomes ........ - 113 6.2.6.1 Synthesis of [18F]-FCP ........................................................................ - 113 6.2.6.2 Labeled Liposome Preparation and Drug Loading ............................. - 113 6.2.6.3 Characterization .................................................................................. - 114 6.2. 6.4 In Vivo Dual Tracer Imaging with Trimodal PET/SPECT/CT .......... - 114 6.2.7
Cell lines and Culture Conditions ......................................................... - 115 6.2.8
Xenograft Animal Model ...................................................................... - 116 6.3 Results ............................................................................................................... - 116 6.3.1
[111In]-Labeled Liposome Characterization .......................................... - 116 6.3.2
Biodistribution Studies.......................................................................... - 116 6.3.2.1 Biodistribution of 111InCl3................................................................... - 116 -

iv

6.3.2.2 Biodistribution of [111In]-DTPA ......................................................... - 118 6.3.2.3 Biodistribution of [111In]-DTPA-DPPE .............................................. - 120 6.3.2.4 Biodistribution of [111In]-Labeled Liposome ...................................... - 121 6.3.2.5 In vivo SPECT/CT Imaging of [111In]-Labeled Liposome ................. - 123 6.3.3 [18F]-FCP encapsulated [111In]-Labeled Liposomes .................................. - 125 6.3.3.1 Size Measurement and ζ Potential. ..................................................... - 125 6.3.3.2 Entrapment and Labeling Efficiency: ................................................. - 125 6.3.3.3 Dual Tracer Imaging ........................................................................... - 125 6.4 Discussion: ................................................................................................... - 128 6.5 Conclusion.................................................................................................... - 132 References ............................................................................................................... - 133 CHAPTER 7: CONCLUSION AND FUTURE WORK ............................................ - 135 7.1 Summary of Conclusion ................................................................................... - 136 7.2 Future Work ...................................................................................................... - 137 APPENDIX ................................................................................................................. - 140 VITA ........................................................................................................................... - 142 -

v

List of Tables
Table 1: Pathological classification of cancer .............................................................. - 10 Table 2: FDA approved targeted therapies that interfere with variety of cellular processes.
....................................................................................................................................... - 21 Table 3: Classification of chemotherapeutic agents used in cancer treatment ............. - 23 Table 4: Commonly used single photon emitting radionuclides .................................. - 39 Table 5: Commonly used positron emitting radionuclides ........................................... - 42 Table 6: Commonly used PET radiopharmaceuticals (adapted from reference 18) ...... - 44 Table 7: Nanoparticle systems for drug delivery applications...................................... - 61 Table 8: Currently used liposomal drugs in clinic ........................................................ - 63 Table 9: IC50 values of cisplatin, carboplatin and 19F-FCP in various cancer cell lines - 88
Table 10: Biodistribution of intravenously injected [18F]-FCP in nude mice (n=3 per time
point). Data are presented as %ID/g (mean±sem) values determined through gamma
counting......................................................................................................................... - 91 Table 11: Biodistribution of tail-vein injected 111InCl3 (1.07± 0.03) in nude mice (n=3
per time point. Data are presented as %ID/g (mean±sem) values determined through
gamma counting. Tissues were collected, weighed and gamma emission was measured in
a gamma counter to calculate % ID/g ......................................................................... - 117 Table 12: Biodistribution of tail-vein injected [111In]-DTPA (1.07± 0.03) in nude mice
(n=3 per time point. Data are presented as %ID/g (mean±sem) values determined through
gamma counting. Tissues were collected, weighed and gamma emission was measured in
a gamma counter to calculate % ID/g ......................................................................... - 118 Table 13: Biodistribution of tail-vein injected [111In]-DTPA-DPPE (1.07± 0.03) in nude
mice (n=3 per time point. Data are presented as %ID/g (mean±sem) values determined
through gamma counting. Tissues were collected, weighed and gamma emission was
measured in a gamma counter to calculate % ID/g..................................................... - 120 Table 14: Biodistribution of tail-vein injected [111In]-Labeled Liposome (1.07± 0.03) in
nude mice (n=3 per time point. Data are presented as %ID/g (mean±sem) values
determined through gamma counting. Tissues were collected, weighed and gamma
emission was measured in a gamma counter to calculate % ID/g .............................. - 122 -

vi

List of Figures
Figure 1: Dual tracer labeled liposomal nanocarrier. [18F]-FCP encapsulated [111In]Labeled Liposome was synthesized and was evaluated in tumor xenograft bearing mouse
model............................................................................................................................... - 7 Figure 2: Cell division of normal and cancer cells ....................................................... - 10 Figure 3: Types of cell death induced by radiation. Radiation mainly kills the cells either
by apoptosis or mitotic catastrophe (adapted and modified from reference 28) ............ - 18 Figure 4: Schematics of targeted therapy of cancer that represents a new generation of
drugs that are believed to interfere with the specific pathway of cancer to interfere with
the growth of tumor progression (adapted and modified 24) ......................................... - 20 Figure 5: Chemical structure of platinum compounds; Cisplatin (A); Carboplatin (B);
Oxaliplatin (C) .............................................................................................................. - 25 Figure 6: Cisplatin adduct formation and binding with DNA. The adducts formed by
cisplatin and carboplatin are same. ............................................................................... - 26 Figure 7: The mechanism by which tumor resistance to cisplatin and carboplatin occurs.
Platinum drugs enter the cell through diffusion or by transporter, major being the copper
transporters (CTR1). After the aquation of the platinum drugs, the activated aqua species
preferentially reacts with species containing glutathiones of metallothioneins, mopping
up the aquated species before DNA binding could occur (adapted and modified from
reference35). ................................................................................................................... - 30 Figure 8: Molecular imaging probes and their cellular targets (copied) ....................... - 38 Figure 9:Schematic representation of SPECT System.................................................. - 40 Figure 10: Principle of PET imaging: positron emitting radionuclide yields a positron that
travels a short distance and annihilates with an electron and produce two collinear 511
keV photons. These photons exit the body and are detected by an array of scintillation
crystals .......................................................................................................................... - 43 Figure 11: Depiction of the non-colinearity of the annihilation photons; scattered
coincidence occurs when one or both of the photons are scattered but are still detected in
the same energy and coincidence window in the detector (A); random coincidence occurs
when two photons arising from coincidence window in the detector (A); random
coincidence occurs when two photons arising from two different annihilation events are
detected in the same coincidence window (B) .............................................................. - 44 -

vii

Figure 12: Overview of metabolic processes targeted by PET and MRI in the study of
tumor metabolism study (adapted and modified from reference10) .............................. - 50 Figure 13: Thymidine salvage and de novo synthesis pathway. [18F]-FLT is transported
into the cells and phosphorylated to [18F]-FLT monophosphate ([18F]-FLTMP) which
can be further phosphorylated to diphosphate and triphosphate. However, due to the
substitution of OH with 18F in 5-position, [18F]-FLT is not incorporated into the DNA.
(adapted and modified from reference 14) ..................................................................... - 52 Figure 14: Chemical Structure of (A) [18F]-FLT; (B) [18F]-FMAU........................... - 53 Figure 15: Cellular events that have been exploited for imaging cell death (adapted and
modified from reference 16) ........................................................................................... - 54 Figure 16: Depiction of a lipoplatin nanoparticle, a liposomal formulation of cisplatin.
Cisplatin is represented as blue sphere surrounded by the lipid bilayer with PEGylated
lipid sticking out hair like structures (adapted and modified from reference29) ........... - 67 Figure 17: Automated synthesis of [18F]-FCP using AllInone Synthesizer. The cassette
for the three step reaction was prepared using manifolds. Machine test was performed to
verify the optimal vacuum, pressure and the movement of all components before placing
the manifold in the synthesizer as shown above. After the placement of the cassette, the
cassette test was performed to test the leak, vacuum in the reactor vials and the syringe
positions. After all the tests were successful, reagent vials were placed as shown above
and the pre programmed sequences for the synthesis was started for the complete
synthesis procedure. ...................................................................................................... - 80 Figure 18: Sample was run on Waters® 4µ C18 150 x 3.9 mm column; ACN/Water
(0.1%TFA) 25/75 with flow rate of 1mL/min; Fig A. RT = 3.38 min. of Radioactivity
[18F]-FPMA; Fig B: HPLC profile of Platinum coordination reaction; Fig. C: HPLC
profile after purification RT=1.43 min of [18F]-FCP. ................................................... - 90 Figure 19: Biodistribution of [18F]-FCP in normal adult female nude mice (n=3) at 5, 30,
90 mins after injection. Radio tracer uptake in % ID/g was determined by gamma
counting......................................................................................................................... - 92 Figure 20: Plasma sample was run on Waters® 4µ C18 150 x 3.9 mm column;
ACN/Water (0.1%TFA) 25/75 with flow rate of 1mL/min at different time point; Fig. A:
05 min; Fig. B: 30 min; Fig. C: 60 min. ....................................................................... - 92 Figure 21: A female nude mouse was injected (i.v) with 5.5-6 MBq of [18F]-FCP
derivative and imaged using an Inveon PET/CT scanner (SIEMENS,USA). Dynamic
image data acquired between 5, 30, 60 and 90 minutes post injection was reconstructed
(FBP and OSEM/MAP) and analyzed. ......................................................................... - 93 -

viii

Figure 22: Nude mice were innoculated with human cervical adenocarcinoma (KB) cell
lines to establish a xenograft model with one P-glycoprotein (P-gp) non expressing (KB
3-1) and one Pgp expressing (KB 8-5) tumor per animal. [18F]-FCP (5.5-6 MBq) was
injected intravenously in xenograft nude mice via tail vein injection. Imaging was carried
out 90 mins post injection using Inveon PET/CT (Siemens, USA). Static summed up
image acquired 90 mins post injection was reconstructed (FBP and OSEM3D/MAP) and
analyzed. Image showed that P-gp non expressing (KB 3-1) tumor has slightly higher
uptake of radiotracer than P-gp expressing KB8-5 tumor. ........................................... - 94 Figure 23: Sequential trimodal in vivo imaging with PET and SPECT probes was
achieved through the above workflow. A. Injection of [18F]-FCP encapsulated [111In]Labeled Liposomes via tail vein injection; B. PET imaging, C. SPECT imaging; D. X-ray
CT imaging (modified from reference 18). .................................................................. - 115 Figure 24: Biodistribution of tail-vein injected 111InCl3 (1.07± 0.03) in nude mice (n=3
per time point. Data are presented as %ID/g (mean±sem) values determined through
gamma counting. Tissues were collected, weighed and gamma emission was measured in
a gamma counter to calculate %ID/g .......................................................................... - 118 Figure 25: Biodistribution of tail-vein injected [111In]-DTPA (1.07± 0.03) in nude mice
(n=3 per time point. Data are presented as %ID/g (mean±sem) values determined through
gamma counting. Tissues were collected, weighed and gamma emission was measured in
a gamma counter to calculate % ID/g ......................................................................... - 119 Figure 26: Biodistribution of tail-vein injected [111In]-DTPA-DPPE (1.07± 0.03) in nude
mice (n=3 per time point. Data are presented as %ID/g (mean±sem) values determined
through gamma counting. Tissues were collected, weighed and gamma emission was
measured in a gamma counter to calculate % ID/g..................................................... - 121 Figure 27: Biodistribution of tail-vein injected [111In]-Labeled Liposome (1.07± 0.03) in
nude mice (n=3 per time point. Data are presented as %ID/g (mean±sem) values
determined through gamma counting. Tissues were collected, weighed and gamma
emission was measured in a gamma counter to calculate % ID/g .............................. - 123 Figure 28: In vivo SPECT imaging of normal nude mice injected with [111In]-Labeled
Liposome through tail vein 2, 48 and 144 hrs post injection. The images showed initial
uptake of activity in RES and subsequent clearance with time. ................................. - 124 Figure 29: The clearance profile of [111In]-Labeled Liposome in specific tissues as shown
in SPECT images measured by ROI analysis. ............................................................ - 125 Figure 30: In vivo CT and PET/CT image of KB 3-1 (sensitive) and COLO 205
(resistant) tumor xenograft bearing nude mouse injected with 10 MBq of [18F]-FCP
through tail vein injection 1 hour post administration. Image shows the uptake of [18F]FCP in kidneys, bladder and marrow. ......................................................................... - 127 Figure 31: In vivo CT, PET/CT and SPECT/CT images of KB 3-1 (sensitive) and COLO
205 (resistant) tumor xenograft bearing nude mouse injected with 14 MBq of [18F]-FCP

ix

encapsulated [111In]-Labeled Liposome through tail vein injection 1 hour post
administration. PET/CT Image shows the uptake of [18F]-FCP encapsulated in [111In]Labeled Liposome RES.SPECT/CT image shows the uptake of [18F]-FCP encapsulated in
[111In]-Labeled Liposome in RES. Both image corresponded to each other in the uptake
profile demonstrating the feasibility of dual tracer imaging from a single nanoconstruct.
(A) Coronal Images (B) Volume Rendered Images ................................................... - 128 -

x

List of Abbreviations
For the convenience of the reader, here are the lists of abbreviations.
[18F]-FCP
19

F-FCP

[18F]-FMISO
FDG
FLT
FMAU
FPMA
PET
SPECT
CT
MRI
DLS
ROI
RES
t1/2
EPR
DNA
RNA
EMT
TGF
EGF
3DCRT
IMRT
IGRT
SRS
SBRT
mAbs
VEGF
EGFR
HER-2
CML
ALL
FDA
5-FU
JM216
ZD0473
HPMA
MDR
PgP
CTR1

cisdiammine {2-(5-[18F]-fluoropentyl)-2-methylmalonatoκ2, O, O’} platinum (II)
cisdiammine {2-(5-fluoropentyl)-2-methylmalonatoκ2, O, O’} platinum (II)
Fluoromisonidazole
Fluorodeoxyglucose
3ʹ-deoxyfluorothymidine
18
F-1-(2ʹ-deoxy-2ʹ-fluoro-β-D-arabinofuranosyl) thymine
2-(5-fluoro-pentyl)-2-methyl malonic acid
Positron Emission Tomography
Single Photon Emission Tomography
Computed Tomography
Magnetic Resonance Imaging
Dynamic Light Scattering
Region of Interest
Reticuloendothelial System
Half Life
Enhanced Permeability and Retention
Deoxyribonucleic Acid
Ribonucleic Acid
Endothelial to Mesenchymal Transition
Transforming Growth Factor
Epidermal Growth Factor
Three-dimensional Conformal Radiation Therapy
Intensity Modulated Radiation Therapy
Image Guided Radiation Therapy
Stereotactic Radiosurgery
Stereotactic Body Radiation Therapy
Monoclonal Antibodies
Vascular Endothelial Growth Factor
Epidermal Growth Factor Receptor
Herceptin-2
Chronic Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Food and Drug Administration
5-FluoroUracil
Satraplatin
Picoplatin
Hydroxypropylmethacrylamide
Multidrug Resistance
P-glycoprotein
Copper Transporter 1

xi

GT
ATP
ABC
BCRP
ERCC
MRP
mRNA
LRP
ICP
γ-rays
EC
IT
βFOV
NaI
2D
3D
CdZnT
LOR
FBP
OSEM
WB-DWI
TK
AnxV
PLA
PLGA
PEG
RGD
QMA
NAH
TBAF
THF
MeOH
LiOH
ACN
NaOH
NMR
RCY
RCP
TLC
HCl
DCM
K18F/K222
CO2
PBS
FBS

Glutathione Transferase
Adenosine Triphosphate
ATP-Binding Cassette
Breast Cancer Resistance Protein
Excision Repair Cross Complementation
Multidrug Resistance Protein
Messenger RNA
Lung Resistance Protein
Induced Coupled Plasma
Gamma Rays
Electronic Conversion
Isomeric Transition
beta-minus
Field of View
Sodium Iodide
Two Dimensional
Three Dimensional
Cadmium Zinc Telluride
Line of Response
Filtered Backprojection
Ordered Subsets Expectation Maximization
Whole Body Diffusion Weighted Imaging
Thymidine Kinase
Annexin V
Polylactic Acid
Poly-(lactic-glycolic)-Acid
Polyethylene Glycol
Arginylglycylaspartic acid
Quaternary Ammonium
Sodium Hydride
Tetrabutyl Ammonium Fluoride
Trihydro Furane
Methanol
Lithium Hydroxide
Acetonitrile
Sodium Hydroxide
Nuclear Magnetic Resonance
Radiochemical Yield
Radiochemial Purity
Thin Layer Chromatography
Hydrochloric Acid
Dichloromethane
Kryptofix
Carbondioxide
Phosphate Buffered Saline
Fetal Bovine Serum

xii

DMEM
COLO205
KB
SCLC
NSCLC
A549
SK-OV
RWPEI
FaDu
A498
LNCaP
IC50
DPPC
DSPC
HSPC
DPPG
CH
DSPE-PEG2000
DTPA-DPPE

Dulbeco’s Modified Eagles Medium
Colorectal Carcinoma
Human Cervical Carcinoma
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Ovarian Carcinoma
Benign Prostate
Head and Neck Carcinoma
Renal Carcinoma
Prostate Carcinoma
Inhibition constant 50
1, 2- dipalmitoyl-sn-glycero-3-phosphocholine
1, 2- distearoyl-sn-glycero-3-phosphocholine
Hydrogenated soy phosphatidylcholine
Dipalmitoyl phophatidylglycerol
Cholesterol
1,2-distearoyl-sn-glycero-3-phosphoethanol-amineN-[methoxy(polyethyleneglycol)-2000]
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-Ndiethylenetriaminepentaacetic acid

xiii

Abstract
Multimodality Molecular Imaging of [18F]-Fluorinated Carboplatin Derivative
Encapsulated in [111In]-Labeled Liposomes
By Narottam Lamichhane, BS
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Medical Physics at Virginia Commonwealth University
Virginia Commonwealth University, 2014
Director: Jamal Zweit, PhD, DSc
Professor, Department of Radiology
Platinum based chemotherapy is amongst the mainstream DNA-damaging agents used in
clinical cancer therapy today. Agents such as cisplatin, carboplatin are clinically
prescribed for the treatment of solid tumors either as single agents, in combination, or as
part of multi-modality treatment strategy. Despite the potent anti-tumor activity of these
drugs, overall effectiveness is still hampered by inadequate delivery and retention of drug
in tumor and unwanted normal tissue toxicity, induced by non-selective accumulation of
drug in normal cells and tissues. Utilizing molecular imaging and nanoparticle
technologies, this thesis aims to contribute to better understanding of how to improve the
profile of platinum based therapy. By developing a novel fluorinated derivative of
carboplatin, incorporating a Flourine-18 (18F) moiety as an inherent part of the molecule,
quantitative measures of drug concentration in tumors and normal tissues can be directly
determined in vivo and within the intact individual environment. A potential impact of
this knowledge will be helpful in predicting the overall response of individual patients to
the treatment. Specifically, the aim of this project, therefore, is the development of a
fluorinated carboplatin drug derivative with an inherent positron emission tomography
(PET) imaging capability, so that the accumulation of the drug in the tumor and normal
organs can be studied during the course of therapy . A secondary objective of this
research is to develop a proof of concept for simultaneous imaging of a PET radiolabeled
drug with a SPECT radiolabeled liposomal formulation, enabling thereby bi-modal
imaging of drug and delivery vehicle in vivo. The approach is challenging because it
involves development in PET radiochemistry, PET and SPECT imaging, drug liposomal
encapsulation, and a dual-modal imaging of radiolabeled drug and radiolabeled vehicle.
The principal development is the synthesis of fluorinated carboplatin 19F-FCP using 2-(5fluoro-pentyl)-2-methyl malonic acid as the labeling agent to coordinate with the
cisplatin aqua complex. It was then used to treat various cell lines and compared with
cisplatin and carboplatin at different concentrations ranging from 0.001 µM to 100 µM
for 72 hrs and 96 hrs. IC50 values calculated from cell viability indicated that 19F-FCP is a
more potent drug than Carboplatin. Manual radiosynthesis and characterization of [18F]FCP was performed using [18F]-2-(5-fluoro-pentyl)-2-methyl malonic acid with
coordination with cisplatin aqua complex. Automated radiosynthesis of [18F]-FCP was

optimized using the manual synthetic procedures and using them as macros for the
radiosynthesizer. [18F]-FCP was evaluated in vivo with detailed biodistribution studies
and PET imaging in normal and KB 3-1 and KB 8-5 tumor xenograft bearing nude mice.
The biodistribution studies and PET imaging of [18F]-FCP showed major uptake in
kidneys which attributes to the renal clearance of radiotracer. In vivo plasma and urine
stability demonstrated intact [18F]-FCP. [111In]-Labeled Liposomes was synthesized and
physiochemical properties were assessed with DLS. [111In]-Labeled Liposome was
evaluated in vivo with detailed pharmacokinetic studies and SPECT imaging. The
biodistribution and ROI analysis from SPECT imaging showed the spleen and liver
uptake of [111In]-Labeled Liposome and subsequent clearance of activity with time. [18F]FCP encapsulated [111In]-Labeled Liposome was developed and physiochemical
properties were characterized with DLS. [18F]-FCP encapsulated [111In]-Labeled
Liposome was used for in vivo dual tracer PET and SPECT imaging from the same
nanoconstruct in KB 3-1 (sensitive) and COLO 205 (resistant) tumor xenograft bearing
nude mice. PET imaging of [18F]-FCP in KB 3-1 (sensitive) and COLO 205 (resistant)
tumor xenograft bearing nude mice was performed. Naked [18F]-FCP and [18F]-FCP
encapsulated [111In]-Labeled Liposome showed different pharmacokinetic profiles. PET
imaging of [18F]-FCP showed major uptake in kidneys and bladder. However, [ 18F]-FCP
encapsulated [111In]-Labeled Liposome showed major uptake in RES in both PET and
SPECT images. ROI analysis of SPECT image enabled by 111In corresponded with PET
image enabled by 18F demonstrating the feasibility of dual tracer imaging from the single
nanoconstruct. Future work involves the intensive in vitro characterization of [18F]-FCP
encapsulated [111In]-Labeled Liposome and detailed in vivo evaluation of [18F]-FCP
encapsulated [111In]-Labeled Liposome in various tumor models.

CHAPTER 1: INTRODUCTION
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1.1

Rationale

Platinum based anti-cancer therapy is a major treatment modality for various solid tumors
in clinic. For many patients however, treatment efficacy is still hampered by normal
tissue toxicity and drug resistance, which limits adequate dose in tumors. In order to
better understand the extent of therapeutic efficacy, in relation to drug concentration, in
vivo live imaging of tissue based drug pharmacokinetics is needed. Therefore, to reduce
the adverse effect caused by platinum drugs, to increase the delivery, and to optimize the
response of tumor, an approach of encapsulating the platinum drug inside the liposome
and combining it with radioisotope would provide theranostic and synergistic effect.

1.2

Objective

The overall objective of this project is to develop a multimodal nanocarrier drug delivery
system to investigate the delivery, retention and efficacy of anticancer therapy through
molecular imaging. The aim of this thesis project is to develop a novel multimodal
therapy/imaging paradigm, where a novel Fluorine-18 labeled Carboplatin derivative,
cisdiammine{2-(5-[18F]-fluoropentyl)-2-methylmalonato-κ2,O,O’}platinum(II)},([18F]FCP) is encapsulated inside Indium-111 labeled liposome ([111In]-Labeled Liposome).
The direction of this project is to combine the radiochemistry strengths that involve the
ability to radiolabel organic molecules with

18

F and other radioisotopes to perform

Positron Emission Tomography (PET/CT) and Single Photon Emission Tomography
(SPECT/CT) imaging in small animal with high spatial resolution, to study the
biodistribution and pharmacokinetics of the pharmaceutical load of the nanocarrier. This
proposal where the radiolabeled drug is incorporated inside the radiolabeled vehicle is
quite novel which would be useful in evaluating the fate of drug by tracking the PET
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signal from 18F, whether it stays with the nanocarrier by tracking the SPECT signal from
111

In or is separated from the nanocarrier and is accumulated in tissues by looking at the

dual tracer profile. The ultimate objective of this project is to provide a quantitative
theranostic agent that is capable of relating the tumor drug availability to efficacy of drug
delivery and treatment. These dual advantages from a single nanocarrier construct will
eventually be translatable to the clinic for the diagnosis of solid tumor and metastasis and
to effectively kill tumors.

1.3

Statement of Aims

The specific aims of the project are as follows:


To synthesize and characterize [111In]-Labeled Liposome nanocarrier to
enable SPECT imaging. Labeling a nanocarrier allows to study the in vivo
kinetic profile of the vehicle. Liposome, as a nanocarrier stays in the blood
circulation for a longer period of time to deliver an effective dose to tumor via
enhanced permeability and retention effect (EPR). Optimal SPECT agents with
medium half life are required for extended imaging of the nano-vehicle.
Therefore, for this project, the liposome was labeled with [111In] (t1/2 = 2.8 days,
171 keV, 90%, and 245 keV, 94%) to determine the pharmacokinetic profile of
the nanocarrier.



To synthesize and characterize [18F]-FCP as a theranostic drug for imaging
and therapy. Our goal is to test the efficacy of drug in tumors. This requires
monitoring the drug’s therapeutic effectiveness in targeted site. Labeling the drug
with

18

F ( t1/2 = 110 mins,97% β+) allows a pathway to determine the drug
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metabolism, route of metabolism, clearance and tissue distribution in vivo. It
provides a non-invasive imaging flexibility to assess the drug accumulation and
retention in normal tissues and tumors using PET.



To encapsulate [18F]-FCP in [111In] - Labeled Liposome nanocarrier to enable
two distinct SPECT and PET signals from one construct. Naked drugs once
injected intravenously cause systemic toxicity due to non specific uptake.
Encapsulation of drugs in nanocarrier reduces the exposure of drugs to normal
tissue. This nanoconstruct (radiolabeled drug encapsulated in radiolabeled
vehicle) provides in vivo data on fate of the drug, vehicle and the construct itself
using multi-modal imaging. In vivo information on accumulation and clearing
profiles facilitates in optimizing the nanoconstruct for future targeted imaging and
delivery.



To evaluate the doubly radiolabeled nanocarrier construct in tumor model
using multimodal imaging. Determination of the behavior of the nanoconstruct
in tumor is essential to determine the effectiveness of the delivery system. We
evaluated our drug packaged liposomal carrier in tumor xenograft model. Dual
tracer imaging using PET/SPECT was performed in nude mice inoculated with
human epidermal cancer cell line KB 3-1 (Cervical Carcinoma) and COLO 205
(Colon Carcinoma) to assess the in vivo pharmacokinetics of the nanoconstruct.

1.4

Innovation
This work is innovative in two aspects:
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It proposes a novel dual modality guided imaging of a fluorinated drug
encapsulated liposomal nanocarrier. Encapsulation of radiolabeled drug in
radiolabeled vehicle will provide two distinct signals from one construct to study
the overall pharmacokinetics of the drug and nanocarrier. This dual- modality
imaging from one construct can offer synergistic advantages over a single
modality.



Synthesis of [18F] - FCP as a novel theranostic anticancer drug for imaging and
therapy. This project is innovative because it proposes a new approach to
individualized therapy by “in situ” measurement of drug concentration, using
molecular imaging, during the course of therapy. This technological advance of
an image-guided platinum drug therapy has been enabled by developing the [ 18F]
- FCP that retains very similar anti-tumor activity to the parent compound in
various human cancer cell lines. This “drug biomarker”, could lead to how patient
therapy can be individualized to affect the best possible response.

1.5

Impact

The impact of this work is tremendous in cancer imaging and therapy of platinum drugs.
The proposed research will impact on how platinum drug therapy can be individually
tailored to cancer patients, by directly monitoring drug treatment using PET imaging. As
of our knowledge, this is the first time that a platinum drug is labeled with

18

F, a non

invasive molecular imaging tracer for PET. The development of [ 18F]- FCP allows
tracking and measuring the drug treatment and its accumulation in tumor and normal
tissues during the course of therapy using non-invasive multimodal imaging. This
capability provides a tool to identify responders from non-responders and will also help
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to understand susceptibility or resistance to treatment. Data from this project will provide
direct measure of drug concentration in heterogeneous individual tumors in relation to
response. Encapsulation of [18F] – FCP inside the liposome will also reduce the exposure
of drug to normal tissue and hence reduce the normal tissue toxicity. In addition,
encapsulation of drug inside the liposome will introduce favorable normal tissue
pharmacokinetic profile compared to the naked drug and increases the tumor uptake of
the drug by EPR effect and help in overcoming the tumor resistance

1.6

Research Strategy/ Experimental Design

This research developed a liposome platform (Fig. 1) for the delivery of anticancer agents.
Liposomes with lipid shell radiolabeled with

111

In were synthesized and were optimized

for in vivo experiments. PEG modified phospholipids were used to provide a steric brush
to minimize the lipid shell interactions from the blood components. Radiolabeled drug
[18F]-FCP was encapsulated inside the [111In]-Labeled Liposomes.

18

F is a positron

emitter and has a potential for PET imaging to evaluate the in vivo kinetics of the drug.
Carboplatin is water soluble that enables its encapsulation inside the liposome by using
the hydration method or passive encapsulation method.

111

In is a gamma emitter which

enables SPECT imaging. Radiolabeling the shell with 111In helps to assess biodistribution
and aim to follow the fate of the particle in vivo to obtain insights into the
pharmacokinetics of the liposomes and to quantify the radioactive distribution in different
tissues ex vivo. The liposome construct was evaluated in tumor xenograft model bearing
nude mice. Biodistribution and imaging characteristics of encapsulated and free drug was
determined in tumor bearing nude mice. Nude mice were inoculated with human
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epidermal cancer cell lines to establish a xenograft model with one sensitive and one drug
resistant tumor to assess the drug resistance and retention.

Figure 1: Dual tracer labeled liposomal nanocarrier. [18F]-FCP encapsulated [111In]-Labeled
Liposome was synthesized and was evaluated in tumor xenograft bearing mouse model.
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CHAPTER 2: BACKGROUND
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2.1

Cancer

Cancer is a disease caused by uncontrollable division of abnormal cells in a part of the
body that has the potential to invade other tissues. Normal cells stop dividing when they
come into contact with like cells by a mechanism known as contact inhibition. However,
in cancer cells, genetic mutation in DNA affects the normal cell growth and division. As
a result, cancer cells do not have normal checks and balances that control and limit the
cell division (Fig. 2). Cell division for both normal and cancer cells is through cell cycle
that goes from resting phase, through active growing phase and then to mitosis. The
inability of cells to divide and copy itself in division results in cell death. Various cancer
cell phenotypes such as cells with unlimited proliferative potential, environmental
independence for growth, evasion of apoptosis, angiogenesis, altered metabolism,
invasion and metastasis to different parts of body are the hallmarks of cancer [1, 2].
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Figure 2: Cell division of normal and cancer cells

Cancer is not one disease unlike many other local or organ specific diseases such as heart
disease, kidney diseases etc. Cancer is a group of many diseases and is classified
according to the fluid or tissue they initially originate from, or from the location in the
body they are first developed. Pathologically, cancers are classified as below (Table 1).
Table 1: Pathological classification of cancer

Types
Carcinoma

Sarcoma

Origin

Sub types

• Epithelial cells in the skin or tissues that • Adenocarcinoma
line or cover the internal organs
• Squamous cell carcinoma
• Basal cell carcinoma
• Bone, cartilages, blood vessels, fat, • Osteosarcoma (bone)
muscles, connective or supportive tissues • Chondrosarcoma (cartilage)
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Lymphoma

• Originates in the cells of lymphatic • Hodgkin’s lymphoma
system that develops in mature immune • Non-Hodgkin’s lymphoma
cells, mainly lymphocyte, spleen, thymus

Leukemia

• Originates in hematopoietic cells • Acute myelogenous
residing in the bone marrow and blood
• Chronic myelogenous
• Acute lymphocytic
•Chronic lymphocytic

Cancer refers to a group of conditions that manifests the malignant behavior and
uncontrolled cell growth leading to invasion. Malignant cells have tendency to move
from their site of origin and disseminate to distant organs and form metastases. This
ability of malignant cells is aided by large number of characteristics they possess.
Migrations, ability to invade stroma and endothelial linings, dissemination through
circulation, survival are some of the underlying physiological and biological properties of
solid tumors that allow them to grow in secondary sites. Epithelial solid tumors have
proved to be a major challenge in cancer treatment. Treatment of solid tumors is based on
the type, location and stage of the tumor. Complexity and non-homogeneity of solid
tumors pose an obstacle in the delivery of an efficient amount of drugs to the cancer cells
in a safe and effective manner. Streamlines of techniques have been proposed for the
delivery of cancer drugs to solid tumors in search of more effective therapies. Local only
therapies such as ablation, radiation have garnered positive responses. However, local
therapy is always not feasible to treat solid tumors, especially the metastases.
Several innovative approaches of delivering drugs into tumors using nanoparticles,
liposomes, and micelles have been developed that can target tumor cells and help provide
the information on the underlying biology of solid tumors.
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2.2

Solid Tumors and Cancer Biology

Tumors comprise of heterogeneous population of cells that, over time, develop means to
sustain their growth and survival despite ongoing immune responses or therapies [3-5].
Malignant solid tumors arise after various phases of genetic changes, which endow them
with resistant, proliferative, and invasive capabilities. Such phases include anaplasia (loss
of structural differentiation), neoplasia (abnormal proliferation), dysplasia (change in
tissue phenotype) and hyperplasia where increased proliferative rate of cells leads to
excess of normal appearing cells. When cells further accumulate genetic changes leading
to abnormal and disorganized tissue growth, the phase is referred as dysplasia. This phase
is followed by carcinoma in situ where cells accumulate further mutations, continue
anaplastic growth, but still be limited within basal lamina; hence preventing from
metastases. Further genetic insults result in malignant tumors, or often referred as cancer,
cells increasingly become resistant to immune system or therapies and invade
surrounding tissues or metastasize to distant organs [6, 7]. Metastases are often what
cause death due to multiple organ failures in cancer patients.
Various theories have been proposed as to how the tumor progression occurs. Although it
is widely accepted now that the solid tumors are comprised of heterogeneous populations
of cells, how the progression of tumor occurs had been debatable. Some of the theories
proposed include linear progression model, multi/oligo-clonal progression model, and
cancer stem cells and punctuated equilibrium model [8, 9]. Although linear progression
model goes through the steps described above, it does little to explain the heterogeneity
of the cells in the tumor mass. Oligoclonal progression model suggests that during
progression of tumors leading to metastases, various populations of cells arise and coexist
[8, 9]. Cancer stem cells and punctuated equilibrium model has garnered momentum as
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of late. In many cases, patient relapse despite the optimal debulking and
chemo/radiation/immune-therapies leading to no residual diseases. This has often
attributed to the cancer stem cells, which are often thought to be more resistant and
capable of giving rise to tumor cells [4, 8, 10, 11]. Stem cells have been described in
various types of cancers including but not limited to breast, ovarian, and colon cancers
[11-14]. They have been recognized to have increased resistance to chemo and radiation
therapies and capable of inducing relapse and metastasis of tumors due to their
regenerative capabilities. Presence of such cells limits the efficacy of traditional therapies.
Hence, current studies have now started to take into account the importance of targeting
such cell in the therapy regimen. Another phenomenon that often occurs during tumor
progression is epithelial to mesenchymal transition (EMT) [15]. Although the causalities
of this phenomenon in vivo is attributed to various growth factors and proteins such as
TGF beta and EGF, many other factors are still being studied [15]. As of now, it has been
clearly shown that EMT allows tumor cells of epithelial origin to be migratory through
acquisition of mesenchymal phenotype and hence aid in metastases and disease severity
by acquiring phenotypes like invasiveness and resistance to apoptosis [15, 16].
Solid tumors are adept in resisting immunotherapies and chemotherapies by means such
as abilities to survive in anoxic to hypoxic conditions, constant mutations and selection of
antigen loss variants to evade immune system, and ability to resist the radiation and
chemotherapies by certain cells such as cancer stem cells which constantly give rise to
new cancer cells whilst helping progression and metastases [17-19]. Solid tumors pose
many problems not only to ones’ immune system by a simple fact that most tumor
antigens are self-antigens; hence immune system does not mount a robust response
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against them. On top of that, solid tumors foster such an environment which poses
difficulties to the therapies that are intended towards eliminating them. Most notable of
such difficulties includes the delivery of the drugs. A precise dose and contained delivery
of therapeutic agents limits the toxicities that are often associated with the cancer
therapies. Recent advances in the field of nanoparticle delivery combined with radiation
therapy have shown promising results in controlled delivery of drugs that are efficient in
selectivity and cytotoxicity. Although these recent advances need to be validated via
clinical trials before wide range of patients can benefit from them, progresses in such
technologies are certainly promising.

2.3

Imaging in Cancer Care

Imaging plays an important role in the diagnosis of cancer. Biomedical imaging has many
advantages including real time monitoring, accessibility without tissue destruction,
minimal or non invasiveness and can function over wide ranges of time and size scales
involved in biological and pathological processes [20]. Various multimodal biomedical
imaging techniques are being used in all phases of cancer management. The goal of
cancer imaging is to detect /and or image the smallest possible number of tumor cells,
ideally before the angiogenesis switch [21, 22]. Major problems in cancer treatment are
late diagnosis of cancer, lack of tools to visualize the treatment efficacy of the
biological/chemotherapy treatment, absence of in vivo revelation of signaling pathways
after radiation, chemo/biological therapy. Imaging provides a biological tool for the early
detection of cancer, in vivo drug distribution, heterogeneity of tumor, and direct way of
visualization of various pathways in vivo. Different metabolic pathways, cell proliferation,
cell death and variety of disorders can be studied to a greater understanding using newly
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emerged biomarkers and molecular imaging modalities which provides a better way of
tailoring an effective treatment of the diseased sites. Molecular imaging modalities
imaging the hall marks of cancer is further explained in Chapter 3. Medical imaging in
cancer care is mainly aimed to determine how far a cancer has spread, guide delivery of
specific treatments, and to predict the response of treatment. Imaging is widely employed
in cancer care for various applications including staging, diagnosis, therapy response and
image guided therapy/ surgery.

2.4

Cancer Treatment and Therapy

The treatment of cancer mainly depends on the type and stage of cancer, possible side
effects of the treatment regimen, the patient’s preference and overall health of the patient
itself. The multidisciplinary approach of treating cancer is very essential in determining
the treatment option for the patient. The most common cancer treatments include surgery,
radiation therapy, biological therapy, and chemotherapy. These therapies may be used
alone, or in combination depending on the stage and sensitivity of cancer towards the
treatment. Adjuvant and neoadjuvant therapies are also a major regime of cancer
treatment. However, various other therapies are also looked upon for the treatment
options such as targeted therapy, immunotherapy, hyperthermia, phototherapy, hormonal
therapy, bone marrow transplantation etc. These therapies are not in the scope of this
thesis and won’t be discussed in detail. Different types of cancer cells have unique
properties that may not be readily treatable using the currently available cancer treatment
procedure. Nanotechnology has emerged as a field with potentials to detect and treat
cancer using nanoparticles. Motivation of using nanoparticles for cancer detection is
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prompted from the ineffectiveness of currently available general treatment regimens,
difficulty in early detection of tumors and numerous side effects.

2.4.1 Surgery
Surgery is the primary treatment for many cancers. Surgical resection can completely
remove some cancers. However, it should be noted that surgery is a local treatment and it
only treats the parts of the body it is operated on. So, if the cancer is on its early stage and
is contained in one area, surgery may be the only treatment required to completely treat
the tumor. However, if the cancer has spread to other parts of the body, surgery may not
be the right treatment option. Surgery is used in clinic for various reasons. Diagnosing of
cancer is done by a surgical procedure called biopsy, where a small piece of tissue is
removed to test for the presence of cancer cells, type of cancer cells, and the rate of
growth. Surgery also reduces or prevents the risk of cancer. If a person is at high risk of
particular type of cancer based on his/her family history/genetics, surgery may be able to
reduce the risk of cancer. Woman with high risk of breast cancer may choose to have
their breast removed. Reconstruction surgery is another field of surgery in oncology
which made it possible to recreate the part of the body that was resected using other body
tissues. Breast reconstructions after mastectomy, bladder reconstruction after bladder
removal are some of the usual reconstruction surgeries done in oncology. Surgery is
performed on the patients to remove or bypass blockage, to control pain caused by cancer
that is pressing on a part of the body. Further, surgery may be used as a part of other
treatments such as insertion of tube for chemotherapy, or biological therapy.
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2.4.2 Radiation Therapy
Radiation therapy is the use of high energy x-rays or other particles to kill cancer cells.
Radiation therapy remains an important component of cancer treatment with
approximately 50% of all cancer patients receiving radiation therapy during their course
of illness; it contributes to 40% of curative treatment for cancer [23]. Radiation used in
the treatment of cancer is ionizing radiation which forms electrically charged particles
that deposit energy in the cells of the tissue it passes through. The deposition of energy
results in the genetic changes (damages deoxyribonucleic acid, DNA) of cells resulting in
cell death. DNA is the biological target of radiation. Radiation therapy kills cancer either
by directly interacting with cellular DNA and causing death or by inducing free radicals
from the excitation or ionization of the water component of the cells which causes
indirect damage to DNA. Regardless of the mechanisms of cell kill, the major goal of
radiation therapy is to deprive cancer cells of their proliferating potential and leading to
cell death. Therapeutic efficacy of radiation is achieved by various cell death pathways
(Fig. 3)
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Figure 3: Types of cell death induced by radiation. Radiation mainly kills the cells either by apoptosis
or mitotic catastrophe (adapted and modified from reference 28)

Radiation can be used not only for treatment purposes but also for palliative treatment
purposes to relieve patients from symptoms caused by cancer. Delivering radiation
treatment can be accomplished either by using external beam radiation or by using
internal beam radiation. External beam radiation delivers radiation treatment to cancer by
aiming high energy rays from outside the body to the location of tumor. Internal beam
radiation also known as brachytherapy delivers radiation treatment inside the body by
using sealed radioactive sources or by sealed sources in catheters directly inserted into
the tumor sites. Alike all cancer therapy, radiation therapy also aims to deliver as much
dose to the tumor while sparing the normal tissues. Various radiotherapy techniques have
been emerged over the period of time that encompasses new imaging modalities, delivery
systems with powerful computers and software in advancing the method of treatment and
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improving the understanding of radiobiology and radiation therapy. Technological
advances such as 3D conformal radiotherapy (3DCRT), Intensity modulated radiation
therapy (IMRT), Image-guided radiation therapy (IGRT), Stereotactic radiosurgery (SRS),
Stereotactic body radiation therapy (SBRT), Special procedures, Particle radiations
(electron, proton, neutron beams) have improved the therapeutic ratio of radiation
treatment.

2.4.3 Biologically Targeted Therapy
Spectacular progress in the field of cancer research unveiled the fundamental molecular
basis of cancer progression. Differences in molecular biology, physiology, morphology,
and pathways between the normal and malignant cells were well exploited which
provided the insights on the behavior of cancer mechanisms and proliferation. Based on
this knowledge, new biologically targeted therapeutic agents have been developed which
specifically targets the gene expression and signaling pathways deregulated in the cancer
cells. Cancer targeted therapies that use small molecules, peptides and antibodies have
made therapy more specific to tumor sparing normal tissues [24].
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Figure 4: Schematics of targeted therapy of cancer that represents a new generation of drugs that are
believed to interfere with the specific pathway of cancer to interfere with the growth of tumor
progression (adapted and modified from reference 24)

Some targeted therapies block specific enzymes and growth factor receptors involved in
cancer cell proliferation. Targeted agents are categorized based on the mechanism of their
action and the cells they target. Most of the targeted agents are small molecule drugs or
monoclonal antibodies (mAbs). These agents perform their action either by inhibiting
enzymes (tyrosine kinase inhibitors, preoteosome inhibitors, signal transduction
inhibitors, growth factors inhibitors etc), by inducing apoptosis, or by inhibiting the
angiogenesis pathways (Fig. 4). Presently, there are few hundred targeted cancer agents
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in market including hundreds of new small molecule drugs and mAbs. Some of the
selected targeted therapies in advanced clinical development are shown in Table 2 below.
Table 2: FDA approved targeted therapies that interfere with variety of cellular processes.

Biologically targeted agent

Target (s)

Indication (s)

Bevacizumab (Avastin)

VEGF

• Colorectal cancer
• Glioblastoma
• NSCLC
• Renal carcinoma

Cetuximab

EGFR

• Squamous cell carcinoma of
of head and neck
• Colorectal cancer

Gefitinib (Iressa)

EGFR

• NSCLC

Imatinib (Gleevec)

Tyrosine Kinases

Trastuzumab (Herceptin)

HER-2

• GI stromal cancer
•Systemic mastocytosis
• Dermatofibrosarcoma
protuberans
• Breast adenocarcinoma
• Gastric adenocarcinoma

Sorafenib (Nexavar)

VEGF, Tyrosine Kinases

• Advanced renal cell cancer
• Hepatocellular carcinoma

Dasatinib (Sprycel)

Tyrosine Kinases (ABL)

• CML
• ALL

Lapatinib (Tykerb)

HER2, EGFR

• Breast carcinoma

2.4.4 Chemotherapy
Despite the success in the development of various therapeutic innovations, chemotherapy
is still a preferred method of therapy for a wide range of cancer [23, 25, 26].
Chemotherapy uses chemical substances that act electively on cells that are going through
- 21 -

mitotic cycle. The objective of chemotherapy in cancer is the selection of cytotoxic drugs
and dose levels which predominantly is used in the treatment of metastases and
dissemination without causing severe host toxicity. For the majority of solid tumors,
chemotherapy is used to reduce the tumor volume and palliate symptoms. Most of the
cases, chemotherapy has been used as an adjuvant to surgical and radiotherapy which
results in the eradication of the subclinical metastases and leads to the prolongation of
survival reducing the risk of recurrence. Chemotherapy can either be palliative or
curative depending on the primary location and the extension of the disease. Depending
upon the therapeutic scheme, chemotherapy can use a single therapeutic agent or a
combination of substances. Primary tumors are heterogenic in nature and consist of
metastatic potential, growth rate, immunogenicity, antigenecity and intrinsic response to
cytotoxic drugs [26]. During the evolution stage of heterogenic tumors, some of them
have favorable response to the cytotoxic agents while others do not. Therefore, for
successful chemotherapy the drugs selected should be active when they are used alone,
have known mechanism of actions and should not have toxicity grade higher than
admissible grade. The maximal therapeutic effect is obtained with moderate drug toxicity
and monitoring of the effects of the drug in the patient. However, the effect of
chemotherapy is not strictly focused on cells or neoplastic tissues but have toxic action on
the majority of normal cells especially on regions where normal physiological
replacement of non-tumor cells occurs at a rapid rate. This results in the non-specific
toxicity of cytotoxic agents. Wide ranges of chemotherapeutic agents (Table 3) are used
in cancer care depending on the type of cancer and the mode of action of the
antineoplastic

agents.

Chemotherapeutic

agents

act

on

metabolism

and

the
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pharmacological and toxicological effect of cytotoxic agent depends on the drug
concentration in the specific site of action. Thus the main aim of local delivery of
cytotoxic agent to the disease site is to increase the local concentration in the specific
area and minimize the exposure to the surrounding normal healthy cells.
Table 3: Classification of chemotherapeutic agents used in cancer treatment

Types of Agents
Platinum Coordinates
Antimicrotubules
Agents

Antimetabolites

Antitumor Antibiotics

Alkylating Agents

Target

Examples

• Binds with DNA

• Cisplatin, Carboplatin
Oxaliplatin
• Binds with microtubules • Taxanes
and stop mitosis
(Paclitaxel,Docetaxel)
• Vincaalkaloids
(Vincristine, Vinblastine)
• Interfere with DNA and • Methotraxate
RNA
• Fluropyrimidines
• Damage cells during the S (5-Fluorouracil, Capecitabine)
phase
• Gemcitabine
• DNA intercalation
• Anthracyclines
(Doxorubicin, Daunorubicin)
• Camptothecins
(irinotecan, topotecan)
• Covalently bind to DNA

• Cyclophosphamide
• Nitrosoureas (Carmustine)
•Alkane sulfonates
(Busulfan)

2.4.4.1 Platinum Therapy
Platinum based compounds such as cisplatin, carboplatin and oxaliplatin are widely used
in clinic for the treatment of various malignancies. Since the accidental discovery of the
biological properties of Cisplatin (cis-diamminedichloroplatinum (II) (Fig. 5)) in 1965 by
Rosenberg et al, the era of platinum based anticancer therapy was introduced in clinic.
Currently, cisplatin is one of the most commonly used anticancer drugs as a single agent,
or in combination for the treatment of wide spectrum of malignancies such as testicular,
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ovarian, bladder, cervical, head and neck, small cell and non small cell lung cancers [27].
However, cisplatin lacks tumor selectivity and the cumulative toxicities of cisplatin such
as nephrotoxicity, ototoxicity, neurotoxicity, peripheral neuropathy limit the adequate
dose administration [27-29]. Long term or high dose therapy may lead to severe anemia.
To circumvent these adverse effects of cisplatin, several second and third generations
platinum based drugs have been synthesized over the past few decades. Several of these
second and third generation drugs are currently in clinical trials, however only few of
these drugs were approved for use in humans.
Carboplatin, (cis diammine-[1,1-cyclobutyldicarboxylato-(2)O,Oʹ] platinum (II)) (Fig. 5),
is a second generation analogue of cisplatin. Carboplatin differs from cisplatin by having
a cyclobutyldicarboxylato, a didentate ligand as the leaving group in place of two
chlorides in cisplatin. Carboplatin is less toxic than cisplatin and exhibits antitumor
activities to same types of tumors as cisplatin. As a result, carboplatin has replaced
cisplatin in various treatment regimes in clinic. Owing to its reduced side effects,
carboplatin is well tolerated by patients and can be used at higher doses than cisplatin
[29]. Hearing loss and peripheral neuropathy are less common with carboplatin treatment,
and nephrotoxicity is less as compared to cisplatin. However, visual changes or loss of
vision has been reported with high doses of carboplatin and myelosuppression,
principally thrombocytopenia is a dose limit factor for carboplatin [29, 30].
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Figure 5: Chemical structure of platinum compounds; Cisplatin (A); Carboplatin (B); Oxaliplatin
(C)

The mode of action for cisplatin and carboplatin is similar. The principal biological target
of platinum drugs is nuclear DNA. After the intravenous injection, cisplatin enters the
cells via passive diffusion. In response to the lower chloride concentration inside the
cytoplasm (20mM) as compared to the serum (100mM), cisplatin undergoes activation
by the aquation of one of two of its chloride leaving groups to form cis[Pt(NH3)2Cl(OH2)]+. This positively charged species is able to bind to the N7 position of
purine bases, especially guanine to form either monofunctional or bifunctional adducts
(Fig. 6) depending on the displacement of either one or two leaving groups [29, 31, 32].
Predominant binding occurs between two adjacent guanine based, forming 1.2 intrastnad
cross links. These adduct cause distortions in the DNA double helix, and blocks
replication and transcription of DNA helix. These distortions are eventually recognized
by a number of cellular proteins that will ultimately trigger apoptotic cell death.
Aquated species of carboplatin and cisplatin are same. However, the rate of aquation of
carboplatin in phosphate buffer with a pH of 7 and at 37ºC is 100 folds slower than that
for cisplatin [33].
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Figure 6: Cisplatin adduct formation and binding with DNA. The adducts formed by cisplatin and
carboplatin are same.

Oxaliplatin, cis-[(1R,2R)-1,2-Cyclohexane1,2-diamine]-[ethanedioato-O,O'] platinum(II)
(Fig. 5) is another FDA approved drug which is known to treat cisplatin resistant tumors.
Structurally, oxaliplatin differs from cisplatin by replacing two ammine ligands with
(1R,2R)-cyclohexane- 1,2-diamine (R,R-dach). Due to this structural difference, the
adducts formed by oxaliplatin differs from the DNA adducts formed by cisplatin and
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carboplatin. The drug mainly forms GpG intrastand adducts with bulky hydrophobic dach
ligand pointing into DNA major grove and preventing the binding of DNA [34].
Oxaliplatin is widely used in clinic for metastatic colon cancer as a single agent or as a
combination therapy with 5-FU and folinic acid.
The two other platinum based drugs that have been approved were nedaplatin and
loboplatin. Nedaplatin, Diamine[hydroxyacetato 92-]O-Oʹ] platinum(II), is a second
generation cisplatin analogue which is approved for the treatment of non-small cell lung
cancer, esophageal cancer and head and neck cancers in Japan. Nedaplatin is more water
soluble that cisplatin and possess similar anticancer properties as of cisplatin with lesser
side effects [29].
Loboplatin, {[2-Hydroxypropanoato(2-)-O1,O2][1,2-cyclobutanedimethanamine-N-Nʹ]platinum(II), has been approved for the treatment of chronic myelogenous leukemia,
inoperable metastatic breast cancer and small cell lung cancer in China.
Thrombocytopenia is the most commonly observed dose limiting toxicity associated with
loboplatin.
2.4.4.2 Development of Platinum Analogues
Motivation for the development of new platinum analogues prompted from the need to
enhance the therapeutic index of the platinum drugs with reduced side effects and to
increase their effectiveness against various platinum resistant tumors. Success of cisplatin
triggered the intensive work on the discovery of new platinum based anticancer drugs.
Cisplatin, Carboplatin, and Oxaliplatin are the first line platinum regimen for the
treatment of various solid tumors. However, various other platinum analogues have been
developed and tested in vivo for various solid tumors and platinum resistant tumors.
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Orally administered JM216 (Satraplatin), sterically hindered ZD0473 (Picoplatin),
ProLindac are three platinum analogues that are undergoing clinical trials in patients with
refractory prostate cancer, small cell lung cancer respectively. Satraplatin is an orally
active platinum drug that has shown antitumor activity against human lung, ovary, cervix,
prostate and several platinum resistant tumors. Satraplatin is currently undergoing Phase
I/II/III clinical trials in conjunction with various other anticancer drugs; docetaxel in the
treatment of prostate cancer, paclitaxel in the treatment of NSCLC [35]. Picoplatin (cisAmminedichlorido(2-methylpyridine)platinum(II)) is a sterically hindered platinum
analogue that has a pyridine ring perpendicular to the plane of platinum atom. In vitro
study demonstrated the antitumor activity of picoplatin in cisplatin and carboplatin
resistant tumor. Currently, picoplatin is in Phase I/II studies for colorectal cancer in
combination with 5-FU and leucovorin, in conjunction with docetaxel for prostate
carcinoma [36]. ProLindac is a nanopolymeric formulation of platinum drug, where the
active moiety of oxaliplatin is bound to the hydrophilic biocompatible polymer
(hydroxypropylmethacrylamide,HPMA) to improve the uptake through EPR effect.
Treatment with ProLindac showed superior tumor growth inhibition with reduced side
effect was observed in mice with B16 melanomas and ovarian carcinomas compared to
oxaliplatin [36]. ProLindac in combination study with paclitaxel is currently in Phase II
clinical trail in advanced ovarian carcinomas. Several other platinum analogues had
undergone clinical trails but discontinued because of the lack of antitumor activity and
because of their toxicity. The development of new and better platinum drugs is still a
demanding area of research. Nanotechnology opens a plethora of opportunities in
developing drug delivery vehicles for the delivery of platinum drugs that will alter the
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biodistribution and pharmacokinetics of the drug and reduce the side effects, and enhance
the therapeutic efficacy. Several nanoparticle formulations of platinum drugs are
currently in clinical trials. A key approach in cancer therapy research is to develop a
drug delivery method that selectively delivers the drug to tumor site while reducing the
toxicity to normal organs. Formulations of anticancer drugs with liposome have
demonstrated significant reduction in side effect and altered pharmacokinetic profile that
provides a unique opportunity to facilitate drug delivery to targeted sites. Therefore, this
project utilizes liposomal drug delivery technology to engineer novel platinum drug
formulation.

2.4.4.3 Multidrug Resistance to Platinum
Resistance to chemotherapy is a problematic aspect in the molecular biology of tumors
and one of the most significant barriers in improving the effectiveness of cancer
treatment [37]. Multiple drug resistance (MDR), both intrinsic and acquired, is a serious
problem in solid cancers. There are several mechanisms by which cancer cells may
express intrinsic resistance to platinum, such as, (i) impaired drug delivery, (ii)
extracellular factors, (iii) decreased drug uptake into tumor cells, (iv) increased drug
efflux, (v) drug inactivation by detoxifying factors, (vi) decreased drug activation or
binding to target, (vii) altered target, (viii) increased damage repair, (ix) tolerance of
damage (x) decreased proapoptotic factors, (xi) increased antiapoptotic factors, (xii)
altered cell cycling and (xiii) altered transcription factors [38]. Moreover, different
tumors in the same individual or even different cells within the same tumor may exhibit
chemoresistance heterogeneity. The tumor cell interactions with host factors in the

- 29 -

humans constitute unique tumor microenvironment, which may contribute to
chemoresistance [38].
Resistance to platinum agents occur through various mechanisms including detoxification
of platinum agents by glutathione or other anti-oxidants, decreased intracellular
accumulation, increased DNA repair or DNA tolerance [38-41]. Platinum drugs enter the
cells via passive diffusion down the concentration gradient. The facilitated transport of
platinum drugs is enhanced by copper transporter-1 (CTR1) protein [39, 42-44]. Platinum
resistant may be associated with the decreased CTR1 expression [45] in various cancers
including lung cancer. Upon entering the cells, platinating drugs become aquated which
interacts with DNA resulting cross-linking and inducing apoptotic cell death.
Metallothiones and glutathione related metabolic enzymes such as glutathione transferase
(GT) have a tendency to bind with the aquated platinum complexes and detoxify the
platinum agents (Fig. 7).

Figure 7: The mechanism by which tumor resistance to cisplatin and carboplatin occurs. Platinum
drugs enter the cell through diffusion or by transporter, major being the copper transporters (CTR1).
After the aquation of the platinum drugs, the activated aqua species preferentially reacts with species
containing glutathiones of metallothioneins, mopping up the aquated species before DNA binding
could occur (adapted and modified from reference35).
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Elevated level of these sulfur containing compounds has been associated with resistance
in lung cancer [38, 39, 42, 45]. ATP-binding cassette (ABC) super families of transport
family proteins are associated with resistance in various cancers. The higher expression
of copper transporter protein ATP7B is implicated to the chemoresistance of cisplatin in
lung cancer[38, 41]. Breast cancer resistance protein (BCRP), a transporter and a member
of ABC) was expressed significantly higher in chemo resistant patient treated for
advanced non-small cell lung cancer NSCLC [41]. Higher expression of excision repair
cross complementation group 1 (ERCC1), a form of DNA repair enzyme, has been
shown to have chemoresistance effect in NSCLC[40, 45]. Subfamily C of ABC
transporters includes multidrug resistance protein (MRP1-3) [46]. Higher expression of
MRP is attributed to platinum resistance in small cell lung cancer (SCLC), NSCLC and
other solid tumors [41, 47, 48]. However, there are several studies that are contradictory
to the above and have failed to identify clear markers for chemoresistance in lung cancer.
In an in vitro study, mRNA and protein expression levels of P-glycoprotein (MDR1),
multidrug resistance-associated protein 1 (MRP1), and lung resistance-related protein
(LRP) were investigated and compared with the chemosensitivity and the
intracellular/intranuclear cisplatin accumulation of patient derived NSCLC cell lines
(Ma-10, Ma-31, and Ma-46). The results of that study indicate that MDR proteins
(MDR1, MRP1, and LRP) may not play an important role in the chemoresistance and
drug efflux of platinum drugs in tumor cells [49].
Despite the multifactorial nature of platinum resistance (Fig. 7), reduced intracellular
drug accumulation is one of the most consistently identified features of cisplatin-resistant
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cell lines [50, 51]. Furthermore, a recent clinical study established the relationship
between tissue platinum concentration and response in NSCLC by analyzing tumor
tissues excised from patients who received neoadjuvant platinum-based chemotherapy
without radiation followed by curative surgical resection [52]. Earlier in 1988, platinum
concentrations were determined in autopsy samples and found that the tumors of patients
that responded to Cisplatin had higher mean tumor platinum concentrations than the
tumors of patients that did not respond to Cisplatin [53]. These studies suggest that
reduced platinum accumulation might be an important mechanism of platinum resistance
and the tumor response to platinum based treatment appears to be directly related to drug
concentrations in the tumor tissue in the clinical setting. However, there is no non
invasive means of determining the concentration of platinum in normal tissues and
tumors in patients. Concentration of platinum in tumors in patients is usually determined
by adducts level in tumor biopsies using ICP. This invasive method of determining the
platinum concentration is not feasible in cancer patients, especially when the tumor has
metastasized. Therefore, this project aims in developing [18F]-FCP that will enable a
quantitative non invasive imaging using PET that will ultimately provide a feasible way
of determining the concentration of platinum in tissue basis.
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3.1

Molecular Imaging in Cancer Therapy

Molecular imaging is an emerging medical discipline that can be defined as the fusion of
visual representation, characterization, and quantification of biological processes at the
cellular

and sub-cellular levels

within intact

living

organisms.

This

novel

multidisciplinary field integrates cellular and molecular biology, medical physics,
bioinformatics, biomathematics with diagnostic imaging techniques to produce a new
imaging paradigm. Molecular imaging provides a platform that reflects cellular and
molecular pathways and in vivo mechanisms of disease present within the context of
physiologically authentic environments through the images produced using latest
technological advancements. In the era of molecular medicine, the information on the
complex biology of disease progression, drug metabolism and working therapies is
crucial. Molecular imaging plays a pivotal role in understanding disease, in terms of
biomarker diagnostics, early detection of disease, individualized treatment and potential
prevention within the intact living subject. Molecular imaging detects not only the
presence of the disease process, but can potentially also quantify its extent and severity,
as well follow the course of disease over time [1]. Molecular imaging allows clinicians to
detect the tumor location as well as to visualize the expression and activity of specific
molecules and processes that influences the tumor behavior [2]. Traditionally, changes in
tumor volume a general way of monitoring treatment response. However, singular
measure of treatment response is not sufficient to predict the overall survival of the
patient. Critical molecular features of neoplasm and its underlying pathophysiological
mechanisms such as angiogenesis, metabolism, proliferation, and apoptosis can be
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studied in details using molecular imaging probes that target those specific pathways (Fig.
8)

Figure 8: Molecular imaging probes and their cellular targets (reproduced from reference 3)

Molecular imaging has the capacity to go beyond macroscopic imaging to noninvasively
characterize biological process at the cellular and sub cellular level. Depending on the
molecular tumor specificity, suitable molecular imaging modalities can be employed to
study the biology. While several imaging modalities are employed to study physiologic
and disease processes, response to therapy; radionuclide imaging stands out as the most
commonly utilized imaging modality to exploit the molecular details.
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3.2

Radiotracer Imaging

Imaging with radioisotopes allows obtaining the functional information unlike x-ray
computed tomography (CT) which only provides the anatomical information. Radiotracer
imaging employs radiotracers/radioligands that have the ability to interact with molecular
targets involved in cancer. The development of imaging modalities such as PET and
single photon emission tomography SPECT allows the in vivo visualization of biological
processes at the molecular and cellular level. Both of these imaging modalities involve
the use of exogenous radioactive nuclides injected intravenously to obtain an image of
the distribution within the body after administration. This project focuses on SPECT and
PET which are further detailed in the sections below.

3.2.1 Single Photon Emission Tomography
Single photon emission computed tomography, commonly known as SPECT is an
imaging technique in nuclear medicine. It is very similar to the conventional planar
imaging using a gamma camera. The fundamental basis for SPECT imaging is the
detection of monoenergetically emitted γ-rays from intravenously injected exogenous
SPECT radionuclides (Table 4).

Table 4: Commonly used single photon emitting radionuclides

Nuclides

Half Life

Emission Energy

Mode of Decay

111

2.80 days

171, 245 keV

EC (100%)

99m

Tc

6.02 h

142 keV

IT (100%)

123

I

13.22h

159 keV

EC (100%)

In
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131

I

8.03 days

364 keV

β- (100%)

EC: Electron Conversion, IT: isomeric transition, β-: beta-minus

Basically, when a SPECT radioisotope decays, one or more γ-rays having particular
energies are emitted in random directions from within the subject after the radiotracer
injection. These γ-rays pass through a multichannel lead collimator (parallel hole or pin
hole in order to give access to give the best spatial resolution/sensitivity/FOV) which
restricts the view of the detector to those events originating form the area to be imaged.
Optimal window is selected based on the direction of the photons reducing the detection
of scattered photons. The selected photons traveling along single line of response
corresponding to the individual aperture in the collimators are detected by sodium iodide
(NaI) crystal. The crystal after the detection of the photons emits light which is amplified
by photomultiplier tubes and is recorded. The gamma detector in SPECT rotates around
the subject to detect the emissions. 2D images would be acquired by rotating the gamma
camera at different angles. The acquired 2D image set is converted to 3D image data
using tomographic reconstruction algorithm (Fig. 9).

Figure 9: Schematic representation of SPECT System

SPECT is a rapidly changing field and various areas of research in the development of
new hardware and image processing algorithms is being carried out. The use of longer
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lived half life radionuclide and lower cot of gamma cameras make SPECT imaging
widely available for pre clinical and clinical use. SPECT benefits from longer half lives
radioisotopes that enable imaging studies to be conducted over longer period of time.
Recent advancements on nanotechnology further advanced the field of molecular imaging
with radiolabeled nanoparticles. Extrinsically or intrinsically radiolabeled nanoparticles
with targeting moieties can interrogate specific molecular and cellular events in living
organisms. 111In-Quantum dots, 125I labeled single walled carbon nanotubes, 111In labeled
monoclonal antibodies linked iron oxide nanoparticles are some of the examples of
nanoparticles used for SPECT imaging in pre clinical animal models [4]. The major
advantage of SPECT is superior spatial resolution and it can potentially allow for
simultaneous imaging of multiple radionuclides. However, for a given size of detector
and FOV, SPECT suffers from tradeoff between resolution and sensitivity [5, 6]. Recent
advances on the development of cadmium zinc telluride (CdZnT) direct conversion
detectors allow higher intrinsic resolution and effectively eliminates the dead space at the
edges of detectors [5, 7, 8]. Recent advances in iterative reconstruction algorithms
provide the flexibility and versatility to SPECT imaging.

3.2.2 Positron Emission Tomography
Positron Emission Tomography, commonly known as PET imaging is a widely used
molecular imaging modality which provides 3D image of functional processes in the
body. PET scanner consists of full detector ring with hundreds of coincidence coupled
detectors. After the administration of positron emitting radionuclide (Table 5), there
would be a tracer uptake by different organs.
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Table 5: Commonly used positron emitting radionuclides

Nuclides

Half Life

Max. Energy/MeV

Mode of Decay

18

F

110 min

0.64

β+

C

20.3 min

0.97

β+

11

13

N

10 min

1.20

β+

15

O

2 min

1.74

β+

Cu

12.7 h

0.66

β+/EC

64

68

Ga

68.1 min

1.90

β+/EC

76

Br

16.2 h

4.00

β+/EC

4.18 days

2.14

β+/EC

124

I

β+: beta- plus; EC: Electron Conversion

The tracer decay naturally producing a positron (positive electron) which travels a certain
distance (depending on its energy) and interacts with a free or loosely bound negative
electron. This annihilation of one positive and one negative electron with each other
results in their masses being converted into two photons, consisting of 511 keV energy
being given off at approximately 180º to each other (Fig 10). After the detection of one
photon by a detector, a small amount of light is produced that is amplified as an electrical
signal and is detected as a single count. After this detection, the system waits for another
single count to occur in another detector. If these two single counts occur in the
prescribed time interval, these photons are paired together and stored as a coincident
event (true detection, Fig. 10). This detected coincident event signifies that annihilation
occurred along the line connecting the two detectors referred to as line of response (LOR).
The integrals of annihilations event is measured along the LOR and is stored in a 2D
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matrix called sonogram. Tomographic reconstruction methods such as filtered back
projection (FBP) and ordered subsets expectation maximization (OSEM) are employed to
reconstruct images from sonogram data [9].

Figure 10: Principle of PET imaging: positron emitting radionuclide yields a positron that travels a
short distance and annihilates with an electron and produce two collinear 511 keV photons. These
photons exit the body and are detected by an array of scintillation crystals

However, there is a probability of scatter or attenuation of the annihilated gamma rays
before exiting the body because of their interaction with the tissues. If one or both of the
γ-rays undergoes compton scattering before reaching the detector, the direction of the
photon is likely to change and the scanner could incorrectly position the resulting
coincidence event to wrong LOR (Fig. 11). Scattered coincidence event adds statistical
noise to the signal. Random coincidence events (Fig. 11) are caused by the incorrect
pairing of the two photons arising from different annihilations within the coincidence
window of the detectors. Likely caused by the attenuation of one of the photons, or
lacking of detection of photon by the system, random coincidence adds noise to PET
image [6].
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Figure 11: Depiction of the non-colinearity of the annihilation photons; scattered coincidence occurs
when one or both of the photons are scattered but are still detected in the same energy and
coincidence window in the detector (A); random coincidence occurs when two photons arising from
coincidence window in the detector (A); random coincidence occurs when two photons arising from
two different annihilation events are detected in the same coincidence window (B)

Owing to the high resolution, high sensitivity instrumentation for γ- ray detection and
unlimited tissue penetration, interest in in vivo imaging using PET is growing. Positron
emitting radiotracers are primarily used to tag small molecules that are recognized by
enzymes or bind to receptors and other targets [10]. As a result, numerous PET
radiotracers have been developed for a wide range of applications (Table 6).
Table 6: Commonly used PET radiopharmaceuticals (adapted from reference 18)

PET Probe

Application

Mechanism

[F-18] fluorodeoxyglucose

Glucose Metabolism

[F-18] fluoride

Bone Scanning

Accumulation as
sugar phosphate
Incorporation into bone
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[F-18] fluoromisonidazole

Hypoxia

Redox indicator

[F-18] fluorothymidine

Proliferation

Incorporation into DNA

[C-11] acetate

Fatty acid oxidation

Uptake and clearance by fatty
acid

[C-11] choline

Protein metabolism

Incorporation into phospholipids

3.3

Molecular Imaging in Image Guided Therapy

Morphological imaging with an assessment of the biological function and metabolism is
an invaluable tool for assessing the overall success of the treatment. Image guided
therapy uses imaging techniques to aid in providing localization and targeting of diseased
tissue, visualizing the extent of malignancies and particularly helps in specificity and
identifying cancer. Image guided surgeries and minimally invasive interventions emerged
over the past few decades replaced the traditional invasive approaches and helped in
monitoring and controlling treatments. In modern medicine, nuclear medicine imaging
techniques such as PET/SPECT, advanced imaging technologies such as MRI, CT
entered into interventional and surgery suites to complement on the already available
imaging techniques such as X-ray and ultrasound. Molecular imaging guided surgeries;
MRI guided focused ultrasound surgeries, recently developed intraoperative imaging
techniques substantially increased the versatility of modern interventional system and
accelerated the process of image guided therapy. Integrated PET-MR promised a new
avenue in radiation oncology for dose planning and therapy owing to the properties like
superior resolution, soft tissue contrast and multi-planar capabilities. An ongoing clinical
trail is using [18F]-FMISO dynamic PET-CT and functional MRI for imaging tumor
hypoxia in locally advanced unresectable non-small cell lung carcinoma [1]. Further
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work on using CT-MR on verifying the delivery of planned dose to the clinical target
volume in prostate cancer, assessing the dose to the organs at risk are some of the
connections between MR diagnostics and dose planning system in radiotherapy which
highlights the use of molecular imaging in image guided therapy [11].

3.3.1 Molecular Imaging in Staging and Tumor Expression
Molecular imaging can improve all aspects of clinical cancer care [12]. Application of
PET-CT in oncology has substantially influenced the management of cancer patients.
PET-CT has the ability to generate morphological and anatomical information in a single
examination that will provide an efficient and accurate approach on tumor staging. FDGPET imaging takes advantage of alterations in glucose metabolism, which is a hall mark
of cancer. Prospective studies have shown the higher sensitivity and specificity of this
imaging principle [12]. Therefore, FDG-PET has high accuracy for staging of various
solid tumors and is intensively used in clinic widely. Several new PET tracers have
emerged that can improve the staging of cancer using PET.

11

C-choline PET has very

high specificity and sensitivity for staging and restaging of prostate cancer. Many studies
have evaluated whole body-diffusion weighted imaging (WB-DWI) as a potential
alternative for the detection of metastatic lesion. Tumor metabolism study using
conventional MRI/MRS may serve as a predictive marker for prostate cancer.
Molecular PET imaging plays a pivotal role in identification and quantification of
specific targets and receptor expression in vivo. Various new imaging probes employed in
nuclear imaging have proven to be useful in detecting the presence of various targets due
to the consequence of drug target interaction.

11

C-raclopride for dopamine D2 receptors

and 125I-SD7015 for cannabinoid receptor are two of the many examples of imaging drug
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probe used to obtain qualitative and quantitative data in the tumors of central nervous
system[13].

64

Cu-VEGF in PET imaging is another approach of an imaging probe that

directly interacts with the target. Vascular endothelial growth factor receptor (VEGFR) is
associated with tumor angiogenesis.
imaging of

64

64

Cu-VEGF directly binds to VEGFR and PET

Cu-VEGF helps in assessing the tumor target expression. However,

synthesizing a new customized imaging probe needs individual characterization for
specificity and sensitivity and is costly and time consuming. Reporter gene imaging
provides an alternative to direct target imaging. Several approaches have been emerged to
encode reporter gene with specific enzymes or for receptor capable of binding the
radioactive ligand. Using molecular imaging techniques such as MRI/ MRS, optical or
radionuclide imaging, reporter genes help in the evaluation of level of expression of
specific genes, receptor activities and protein-protein interactions [14].

3.3.2 Tumor Metabolism Imaging
High specific and sensitive imaging of increased metabolic rates for glucose, amino acids,
or lipids associated with malignant tissues have led to a remarkable success of tumor
metabolism imaging in recent years. PET imaging with glucose analog, [18F]-FDG, is the
most commonly used imaging technique to study glucose metabolism of cancer cells in
vivo. After intravenous injection, [18F]-FDG is recognized and is transported across the
cell membrane by sodium independent glucose transporters mainly Glut-1, Glut-3 which
is phosphorylated by hexokinase to form [18F]-FDG-6-phosphate. FDG-6-phosphate is
not a substrate for glycolysis and cannot go further glycolytic pathway because of the
fluorine atom at the C2 position prevents [18F]-FDG-6-phosphate from further
degradation. As a result, the metabolite gets trapped within the tumor cells which is
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exploited for tumor metabolism imaging by PET imaging [15]. PET imaging using [18F]FDG has been used as an indicator of therapy response. PET imaging of FDG takes
advantage of one of the hall mark of cancer, namely the Warburg effect; increased
glucose metabolism and conversion of glucose carbon to lactate are the characteristics of
cancer cells as compared to normal cells [12]. This characteristics of malignant cells is
attributed to the overexpression and increased activity of glucose transporters in the cell
membrane of malignant cells [16].

However, specificity of [18F]-FDG still remains.

After the therapeutic intervention, tumors usually show inflammatory responses leading
to a transient increase in glucose metabolism. [18F]-FDG also accumulates in non-cancer
tissues (usually tissues with high metabolic activity such as inflammatory lesions, brain,
heart) and the interpretation of the imaging signal may be confounded by metabolic flare
phenomena [17].
Various other alterations such as changes in amino-acid transport, protein synthesis,
including the overexpression of cholin kinase (ChoK) is observed in malignant tumors.
Complementary information on tumor biology is further useful for the diagnosis and
therapy monitoring of tumors. Non-selective uptake of [18F]-FDG lead to efforts to
establish amino acids based tracers for tumor metabolism imaging (Fig. 12). Tumor cells
have increased amino acid transport.

11

C-labeled and

18

F labeled amino acids such as

methionines, tyrosines, and methyltyrosines are widely used for accurate metabolic
cancer imaging [17]. Tracers were mainly used in brain tumors in which they showed
excellent contrast between normal brain and tumors and exhibited higher sensitivity in
tumor detection. Therefore, amino acids have the probable advantage over FDG in the
imaging of brain tumors since the background tracer accumulation is lower as compared
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to FDG. Although amino acids have a potential in differentiating between inflammation
and malignancy, various studies have suggested that uptake of amino acid might occur in
benign regions such as ischemic brain, infarction, scar and in irradiated studies [15].
Therefore, monitoring of treatment response of tumor using amino acid must be validated
with further studies.
Phosphocholine is the most abundant phospholipid found in the cell membrane. Elevated
level of phophocholine have been detected by various spectroscopic studies in variety of
tumors, including breast, prostate and brain tumors [18]. Imaging approach based on the
increased need of cancer cells for the cell membrane component phosphatidylcholine,
increased transport and phosphorylation of choline lead to synthesis and pre clinical and
clinical evaluation of choline based tracers. Radiolabeled choline and choline analogs
(11C-choline, [18F]-choline, [18F]-fluoroehtylcholine) have been used to study tumor lipid
metabolism by PET and have shown rapid accumulation in variety of human cancers
including prostate, gliomas, non small-cell lung cancer and esophageal cancer [19].
Recent studies have also shown the avid uptake of
Studies on the uptake of

11

C-acetate in various malignancies.

11

C-acetate correlated the uptake with the fatty acid synthase

expression levels in cancer cells and attributed the observation to the anabolic pathway
which uses acetate for synthesis of fatty acids and lipids [19].
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Figure 12: Overview of metabolic processes targeted by PET and MRI in the study of tumor
metabolism study (adapted and modified from reference 10)

3.3.3 Tumor Proliferation Imaging
Abnormal cellular proliferation is a hall mark of cancer. Imaging and measuring
proliferation is a potentially broad and specific target for the assessment of tumor
progression and response to therapy. DNA synthesis is the most directly related
metabolic process to cell division. Most of the non-invasive methods of imaging the cell
proliferation have focused on the thymidine (TdR) salvage pathway of DNA synthesis
because TdR contains the only pyrimidine or purine base that is unique to DNA [20].
11

C-thymidine, which was used for detecting tumors and for the assessment of therapy,

was limited by the short half life and rapid catabolism of TdR upon injection. Several
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analogs of TdR have been radiolabeled with isotopes for imaging tumor proliferation.
However, the most studied TdR analogs till this point are 18F-labeled3ʹ-deoxyfluorothymidine ([18F]-FLT) and 18F-1-(2ʹ-deoxy-2ʹ-fluoro-β-Darabinofuranosyl) thymine ([18F]-FMAU).
Insight on the pharmacokinetics of [18F]-FLT indicates the prospective assessment of
disease response and identification of rapidly proliferating tumor cells. [18F]-FLT PET
provides the data on the activity of thymidine kinase (TK) activity. After injection, [ 18F]FLT enters the cell and is phosphorylated by thymidine kinase 1(TK1) to [ 18F]-FLTmonophosphate [21]. Additional kinases act on [18F]-FLT-monophosphate and convert
[18F]-FLT-monophosphate to diphosphate and triphosphate (Fig. 13). Replacement of
hydroxyl group at the 5ʹ position (Fig. 13) of deoxyribose prevents [18F]-FLTtriphosphate from cleavage by thymidine phosphorylase and from incorporating into
DNA therefore making it as a substrate for TK1. This phosphorylation makes [ 18F]-FLT
too polar to exit the cell via membrane and hence gets trapped in the cell. Since, TK1
(cytosol) is a key enzyme in the DNA synthesis through the salvage pathway in cell, the
degree of accumulation of [18F]-FLT behaves as a biomarker for proliferation.
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Figure 13: Thymidine salvage and de novo synthesis pathway. [ 18F]-FLT is transported into the cells
and phosphorylated to [18F]-FLT monophosphate ([18F]-FLTMP) which can be further
phosphorylated to diphosphate and triphosphate. However, due to the substitution of OH with 18F in
5-position, [18F]-FLT is not incorporated into the DNA. (adapted and modified from reference 14)

[18F]-FMAU has been developed for proliferation imaging with labeling at 2ʹ-fluoro
position of the sugar with

18

F (Fig. 14). Preliminary clinical studies have shown that the

accumulation of [18F]-FMAU in tumors comparable to that seen in human studies with
[18F]-FLT [20]. [18F]-FMAU, having a 3ʹ-hydroxyl group acts as a substrate for
thymidine kinase 2 (TK2) in mitochondria and gets incorporated into DNA. However, the
primary limitation of [18F]-FMAU is that it appears to be the poor substrate for cytosolic
TK1. Cytosolic TK1 is dependent on cell cycle with higher expression during S, G2, M
phases in dividing cells. Mitochondrial TK2 expression is independent of cell cycle.
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Therefore, the visualization of TK2 activity using [18F]-FMAU with PET imaging may be
less accurate index of cell proliferation [22]. [18F]-FLT PET provides data on TK1
activity and [18F]-FMAU provides data on TK2 activity. TK1 and TK2 are independent
enzymes and the information received wit changes in [18F]-FLT and [18F]-FMAU
respectively provides different biological information on cell proliferation and
mitochondrial mass in tissue. Therapeutic regimen using cytotoxic agent changed the TK
activity. Hence, the biological effect of therapy on [18F]-FLT and [18F]-FMAU
accumulation and its implication must be validated further with scientific discussion [22].

Figure 14: Chemical Structure of (A) [18F]-FLT; (B) [18F]-FMAU

3.3.4 Cell Death Imaging
Cell death imaging plays an important role in detecting the onset of cell death in tumor.
Cell death is an essential biological and pathological process in an organism that is
critical for the correct formation of organs and tissue development. Cell death is hall
mark of various pathological conditions including cancer. Imaging that can locate and
identify cell death will greatly increase the understanding of cell death and its
implications on diseases and therapeutic responses. Currently, there is no probe that has
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been approved for routine cell death imaging in clinic. Various cell death biomarkers and
probes have been developed exploiting various cellular events (Fig. 15) and tested in vivo.
Few of the imaging probes reached clinical trials but failed. The major challenges in
developing a cell death imaging agent include the choice of a relevant molecular target,
the accurate detection of the temporal and spatial occurrence of cell death, optimization
of probe pharmacokinetics, and the minimization of non specific tissue binding and
maximization of tissue contrast [23].

Figure 15: Cellular events that have been exploited for imaging cell death (adapted and modified
from reference 16)

Annexin-V(AnxV) is the most widely used probe for phosphatidylserine-based detection
of apoptosis that has reached phase III clinical trial. AnxV forms trimer-based lattices on
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the surface of apoptic cells, inducing strong cooperative phosphatidylserine binding and
driving cellular internalization. Despite its early promise for detecting apoptosis, AnxV
showed suboptimal pharmacokinetic profile and non specific binding to tissues[24].
Synaptotagmin-I (SynI) is a synaptic-vesicle associated membrane protein that contains
C2A and C2B domain and is responsible for Ca2+ dependent binding to
phosphatidylserine and phosphatidylinositol. Approaches on radiolabeling the C2A
domain with

99m

Tc or

18

F for visualizing cell death in animal model resulted in

heterogenous probe mixtures. Reccent studies on fluorescently labeling that C2Am
domain had better specificity for detection of apoptosis and necrosis [25].

18

F-ML-10, a

PET based tracer was introduced as small molecule agent capable of detecting the plasma
membrane depolarization and acidification of the apoptotic cell [24, 26]. Assessment of
correlation of early changes after radiation therapy using 18F-ML-10 in various solid
tumors is currently taking place [23]. Uptake of Caspase-3/-7specific PET radiotracer
18

F-ICMT-11

((18F-(S)-1-((1-(2-fluoroethyl)-1H-[1,2,3]-triazol-4-yl)methyl)-5-(2(2,4-

difluorophenoxymethyl)- pyrrolidine-1-sulfonyl)isatin) after drug treatment was almost
double, predicting the early detection of drug induced tumor apoptosis in xenograft
models of lymphoma [27]. Structurally well defined probe development and its clinical
translation for simultaneous imaging of cell death will help clinicians diagnose onset of
diseases and tailor individualized treatment options.
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CHAPTER 4: NANOPARTICLE DELIVERY OF ANTICANCER DRUGS
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4.1

Drug Delivery Systems

The effectiveness of anticancer therapy depends on adequate delivery of therapeutic
agents and enhanced retention in solid tumors. Conventional chemotherapy drugs suffer
from lack of selectivity hence they cause significant damage to the normal proliferating
cells of tissues and organs. In addition, some mainstream drugs also suffer from limited
aqueous solubility and require solvent formulations that contribute to toxicity (e.g.
paclitaxel formulation in Cremophor oil). The poor efficacy is further exacerbated by
increased drug efflux due to activation of transmembrane protein efflux pumps, such as
Pgp, MRP, BCRP etc. and detoxification by glutathione; resulting in less drug retention,
and ultimately leading to drug resistance. Tools to address some of these problems
require rationale approaches to quantitatively measure tumor and normal tissue
concentrations of systemically administered drugs. Advancements in the development of
nanoscale drug delivery vehicles, with distinct physical and biochemical properties for
delivery applications, have the potential to improve the therapeutic index of currently
available drugs by increasing the drug efficacy. Examples of these nano-carriers include
nanoparticles, such as polymers, inorganic molecules, microbubbles, micelles,
dendrimers, and liposomes. Platinum drugs are a major class of anticancer drugs in clinic.
However the treatment efficacy of platinum drugs is hampered by multidrug resistance
and increased normal tissue toxicity. This thesis project exploits the field of
nanotechnology and introduces radiolabeled liposome ([111In]-Labeled Liposomes) as a
drug delivery vehicle for novel fluorinated carboplatin derivative to study the
pharmacokinetics and efficacy of liposomal platinum.
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4.2

Nanoparticles in Drug Delivery

Colloidal particles with size ranging between 1 to 100 nm are known as nanoparticles [1,
2]. Nanoparticles have emerged as a promising approach to overcome the delivery
barriers in solid tumors and specificity limitations of conventional drugs. Various types
of nanoparticles based on metals, lipids, polymers and biological nanoparticles have been
investigated for drug delivery systems. Each of these nanoparticles has its own
advantages and disadvantages depending on its application. A brief comparison of these
nanoparticles on drug delivery application is shown in Table 7. Nanoparticles have the
potential to reduce drug toxicity and achieve steady state therapeutic levels of drugs over
an extended period of time. The small size of nanoparticles offers advantages like
increased cellular uptake and accessibility to locations that are not available to larger
particles [2]. Flexible surface chemistry of nanoparticles allows possible conjugation of
ligands and targeting molecule forming potentially effective new chemical entities that
ultimately improves drug solubility, circulation time, stability and biodistribution of
particles in the body. The surface properties and size of nanoparticles plays an important
role in the blood opsonization process and clearance kinetics. The small size of
nanoparticles allows penetration of cell membrane, binding and stabilization of proteins
and lysosomal escape after endocytosis [3]. Opsonization of hydrophobic particles occurs
more quickly than that of hydrophilic particles. Increasing the hydrophilicity by
modifying the nanoparticle surface with chains of hydrophilic and flexible polymers
reduces surface adsorption of blood serum proteins and shield nanoparticles from
opsonins reducing clearance by monocytes and macrophages. The ability to functionalize
the nanoparticles with targeting moieties, imaging agents, and drug payloads enables the
synthesis of multimodal complexes that may provide patients with improved treatment
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specificity and highly sensitive imaging capabilities to monitor treatment progress and
outcomes [4]. Conjugating targeting molecules to the surface of nanoparticles enables
manipulation of biodistribution by exploiting difference in molecular interactions
between normal and malignant cells [5]. Nanoparticle targeting can be done with active
and passive mechanisms. Passive targeting mechanism, known as enhance permeability
and retention (EPR), takes advantages of the leaky vasculature and poor lymphatic
drainage of cancer tissues. Active targeting mechanism has targeting molecules
conjugated to the surface of nanoparticles and takes advantage of molecular recognition
interactions such as ligand-receptor and antibody-antigen [6, 7]. However, defining
highly specific and nonimmunogenic targeting agents that are able to transport
nanocarriers to target tissues still remains as one of the challenges in nanomedicine.

Table 7: Nanoparticle systems for drug delivery applications

Types of
nanoparticles

Advantages

Disadvantages

Applications

Inorganic
Nanoparticles
Eg silica based,
cadmium
based, metal
based, ceramic
based
Polymeric
Nanoparticles
Eg PLA, PLGA

• Inert and
biocompatible
• Easy surface
modification
• Stable over broad
range of temperature
and pH
• FDA approved
• Biodegradable
• Easy surface
modification
• Entrapment of polar
and non polar drugs
• FDA approved
• Controlled release
• Targeted delivery
• Ease of synthesis
and modification

• Slow biodegradation
• Repeated
administration causes
toxicity

• MR contrast
agents
• In vivo cancer
detection
• Thermal therapy
• Targeted delivery

• Polymer toxicity
• Low entrapment load
• Rapid release
• Immunogenicity

• Targeted drug
delivery
• In vivo cancer
diagnosis

• Short blood half life
• Gas core exhaled
through lungs

• Targeted drug
delivery
• Contrast agents

Microbubbles
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Dendrimers

Micelles

Liposomes

4.3

• Easy surface
modification
• Precise size control
• High drug carriage
due to branched
structure
• FDA approved
• Entrapment of both
polar and non polar
drugs
• Thermodynamically
stable

• In vitro toxicity
• Compatibility issues
may cause hemolysis

• Targeted drug and
gene delivery

•Low hydrophobic
core
• Limited drug loading
• Drug precipitation in
physiological fluid

• Targeted drug
delivery

• FDA approved
• Biodegradable, non
toxic, non antigenic
• Surface amenable
for modification
• Low systemic
toxicity
• Prolonged half life
• Entrapment of both
hydrophilic and
hydrophobic drugs
• Controlled drug
release

• Short shelf half life
• Inflammation

• Gene delivery
• Controlled drug
delivery
• Targeted drug
delivery

Liposomes in Drug Delivery

Liposomes are spherical self closed structures composed of phospholipids that form
multilamellar, concentric bilayer vesicles, with lipid layers separated by layers of
aqueous media [1, 8-10]. The chemical composition, structure and colloidal size of
liposome can be controlled by preparation methods that will be useful in various
applications. Controlling the reaction conditions, liposomes can be manufactured with a
different diameter ranging from several nanometers to micrometers. They benefit from
spherical membrane, surface characteristics which may be charged or uncharged based on
the selection of phospholipids. Amphiphilic characteristics of liposomes allow them to
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solubilize a wide range of compounds. Owing to its amphiphilic characters, liposomes
offer several advantages as a drug delivery vehicle. Liposomes can be used to load both
hydrophobic and hydrophilic drugs. Therefore, liposomal drug delivery system is widely
used in delivering anti-cancer agents. Liposome are the first therapeutic nanomedicine to
reach commercialization with the FDA approval of Doxil in 1995 [11]. The success of
liposomes as a drug delivery vehicle can be attributed by its successful translation to
clinic (Table 8).
Table 8: Currently used liposomal drugs in clinic

Product

Drug

Indications

Doxil/Caelyx

Doxorubicin

Kaposi’s sarcoma

Myocet

Doxorubicin

Metastatic breast cancer

Daunoxome

Daunorubicin

Kaposi’s sarcoma, breast
and Lung cancer

Amphotec

Amphotericin-B

Fungizone

Amphotericin-B

AmBisome

Amphotericin-B

Fungal infections,
Leishmaniasis
Fungal infections,
Leishmaniasis
Fungal infections

Abelcet

Amphotericin-B

Fungal infections

VENTUS

Prostaglandin-E1

ALEC

Dry protein-free powder of
DPPC-PG

Systemic inflammatory
diseases
Expanding lung diseases in
babies

Topex-Br

Terbutaline sulfate

Asthma

Depocyt

Cytarabine

Cancer Therapy

Novasome

Smallpox vaccine

Smallpox
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Mikasome

Amikacin

Bacterial infection

VincaXome

Vincristine

Solid Tumors

Autragen

Tretinoin

Kaposi’s sarcoma

Liposomes have been, and continue to be the most intensively researched drug delivery
systems over few decades. However, conventional liposomes are cleared rapidly from the
circulation by the macrophages which are located mainly in the liver, spleen and bone
marrow [8, 12, 13]. The use of modified flexible hydrophilic polymers such as
polyethylene glycol (PEG) which provides a protective hydrophilic layer at the surface of
the liposome reduced the clearance of liposome from reticuloendothelial system (RES) [9,
14, 15]. Such PEGylated liposome, also known as Stealth liposome, have prolonged
circulation time [10, 16], an improved pharmacokinetic profile compared with that of a
free drug [17].
Tumor cells grow indefinitely by forming new vessels to provide nutrients for growth by
a process called angiogenesis. During the formation of these new vessels, solid tumors
have the presence of intercellular gaps in the endothelium. One of the major
characteristics of solid tumors is the lack of effective lymphatic drainage. The
intracellular gaps along with this lack of lymphatic drainage provide a leeway for the
extravasation of molecules with a large particle size into tumor cells. This passive
accumulation phenomenon in solid tumors is known as enhanced permeability and
retention effect (EPR). The EPR effect is considered a heterogeneous process because of
the high variability between different types of tumors, from patient to patient, and within
the tumor itself where there is a vast difference in vascular permeability [18-20].
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Therefore, the EPR effect associated with liposome results in different pharmacokinetics
of the liposomal formulation of drugs compared to the naked drug. The ability to modify
the surface of the liposome enables selective targeting of the liposome and liposomal
anticancer drugs via specific ligands against antigens expressed on malignant cells.
Targeting strategies are exploited to optimize the drug bioavailability to obtain higher
accumulation of liposome accumulation. However, it should be noted that improved
therapeutic efficacy is not necessarily a consequence of increased liposomal delivery to
the target but seem to be model dependent [21]. Several studies have described the
potential methods of active targeting the liposome with specific antibodies (HER-2),
targeting peptide (RGD), and ligands targeting proteins expressed on cancer cell
membrane (folate). Although some studies showed a marginal improvement in survival
with ligand targeted liposome, for many targets, ligand mediated targeting of liposomes
will result in little or no therapeutic improvement over passive targeting [22]. Various
strategies have emerged with liposomal drug delivery to obtain elevated tumor to normal
drug ratios. Externally triggered light and thermo sensitive liposome, receptor targeted
pH and endogenous enzymatically triggered liposomes are some of the advanced and
prospective strategies explored on liposomal drug delivery.
Acid triggered release of the liposomal content has been one of the most widely
investigated release mechanism of liposome. pH sensitive liposomes, after internalization
witnesses the change in the acidic environment where the enzymatic activity releases the
content of liposomes. Another approach of acid triggered liposomes is the use of
fusogenic lipid to synthesize liposomes. Lipoplatin, currently in phase III clinical trial, is
an example of fusogenic liposome that fuses with the lipid layer of the cell membrane,
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internalizes and releases cisplatin on the cytoplasm. Light triggered mechanism of release
is based upon the isomerization, fragmentation of polymerization of lipids upon
photoexcitation. PEG- liposome formulation containing bis-SorbPC, a photosensitive
lipid can polymerize and causes leakage in the lipid bilayer upon UV-excitation [23].
Plasmogen photooxidiation as a triggered release strategy proposed by Thompson and coworkers [24] relies on an increase in membrane permeability upon photooxidative
cleavage of plasmenylcholine to single chain surfactants. Hyperthermia or heat triggered
release has significant advantage over other triggering concepts in that liposome tumor
accumulation was increased due to the increased blood flow and vascular permeability
[21]. Several liposomal formulations using DPPC/DSPC lipids have been designed and
studied in vitro to determine the rate of release when heated at 42ºC for 30 min [25, 26].
Hyperthermia as a triggered release is limited to tumor site that is accessible to local
hyperthermia. Enzymatic release via the upregulated enzymes in tumor tissue is another
triggered release mechanism. This mechanism utilizes the cell associated proteases for
the enzymatic drug release from liposomes [27].
Liposomal formulations of drug offer the advantage of increasing the efficacy of
chemotherapeutic drugs while reducing the toxic side effects. This strategy of liposomal
formulation of drugs has been used for various platinum drugs. SPI-077 is a PEGylated
liposomal formulation of cisplatin which is composed of HSPC, CH and PEG-derivatized
phosphatidylethanolamine (PEG-PE). Although SPI-077 exhibited longer circulation half
life, higher anti-tumor efficacy and a decrease in toxicity compared to free drug, SPI-077
revealed only modest anti-tumor efficacy in phase I and II studies [28].
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Lipoplatin, PEGylated liposomal formulation of Cisplatin, is composed of anionic
phospholipid dipalmitoyl phophatidyglycerol (DPPG), HSPC, CH and PEG-derivatized
phosphatidylethanolamine (PEG-PE) as depicted in Fig. 16. Lipoplatin, nanoparticle with
110 nm diameter, has the ability to target tumors and metastasis via EPR effect after
intravenous administration. Lipoplatin has shown increased concentration in tumors and
metastases at levels up to 200 fold higher compared to the adjacent normal tissue [29].

Figure 16: Depiction of a lipoplatin nanoparticle, a liposomal formulation of cisplatin. Cisplatin is
represented as blue sphere surrounded by the lipid bilayer with PEGylated lipid sticking out hair
like structures (adapted and modified from reference29)

The increased accumulation of Lipoplatin is attributed to the anionic lipid DPPG which
has the ability to survive the lysosome, endosome or cytoplasmic enzyme and to cross the
cell membrane allowing the encapsulated cisplatin to enter the nuclei [18]. During Phase
I and II trials, Lipoplatin has shown anti-tumor efficacy similar to that of a free drug in
advanced squamous cell carcinoma of the head and neck with reduced renal and
hematological toxicity. Therefore, Lipoplatin has progressed into Phase III clinical trial.
Lipoxal, a liposomal formulation of oxaliplatin was developed using similar technology
as Lipoplatin and is composed of HSPC, CH, DPPG, PEG-PE. The mechanism of cell
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uptake and internalization is similar to Lipoplatin since both formulations use the same
lipid components. Preclinical studies carried out on tumor bearing mice proved Lipoxal
to be less toxic to normal tissues without losing its efficacy. However, in Phase I clinical
trial, mild myelotoxicity, nausea and few cases of peripheral neuropathy were observed at
doses of 300-350 mg/m2 [30]. No serious side effects were observed below 300 mg/m2.
Further studies should be done to demonstrate the antitumor efficacy of Lipoxal.
Various other targeted liposomal formulations of platinum derivatives are reported in
literature. Suzuki et al reported transferrin conjugated oxaliplatin encapsulated PEgylated
liposome and its superior antitumor efficacy than non-targeted and free oxaliplatin in in
vivo model [31]. Folate receptor targeted liposomal formulation of carboplatin reported
by Chaudhury et al showed improved therapeutic efficacy in ovarian tumor xenograft
model compared to free drug or non- targeted liposomes [32]. There are currently no
targeted liposomal platinum derivatives approved for clinical use. Studies involving the
targeted liposomes should be further investigated before clinical translation.
This project introduces liposomes as a drug delivery vehicle for a newly synthesized
radiolabeled platinum drug, [18F]-FCP. The liposome surface is radiolabeled with 111In to
enable distinct SPECT imaging in contrast to PET imaging from [18F]-FCP. This enables
real time visualization of the radiolabeled drug and nanoparticle using bi-modal non
invasive imaging. Further details on the synthesis and evaluation of [18F]-FCP and the
liposomal formulation are discussed in Chapter 5 and 6 respectively.
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CHAPTER 5: FLUORINATED CARBOPLATIN
DERIVATIVE: A NOVEL THERANOSTIC ANTICANCER
DRUG FOR THERAPY AND IMAGING
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5.1

Introduction

This chapter deals with the development and evaluation of fluorinated carboplatin
derivatives. This chapter presents the development of cold reference compound, F-19
labeled carboplatin, cisdiammine {2-(5-fluoropentyl)-2-methylmalonato- κ2,O, O’}
platinum(II) (19F-FCP), and its in vitro cytotoxicity evaluation in comparison with
cisplatin and carboplatin. Further, this chapter also presents the development of F-18
labeled carboplatin derivative ([18F]-FCP) and its in vivo evaluation in normal and
xenograft model.
Platinum based anti-cancer drugs play a pivotal role in the treatment of various solid
tumors in clinic today. Since the accidental discovery of its biological properties by
Rosenberg et al [1] many years ago, Cisplatin has made a major impact in the therapeutic
treatment of testicular and ovarian cancers, and along with carboplatin, is still widely
used today for the treatment of ovarian, cervical, head & neck and lung cancers including
advanced non-small cell lung cancer (NSCLC). Like other cytotoxic agents, however,
adequate dosage administration of platinum chemotherapy is still hampered by the toxic
effects of the drug on normal tissues and functions. Both tumor regression and normal
organ toxicity are directly related to amount of drug that reaches the tissues. Reduced
retention of drug in the tumor is further compromised by drug efflux due to multi-drug
resistance (MDR) and limited drug penetration. Currently, there is no direct means by
which the amount of platinum drug in the tumor and normal tissues can be determined in
individual patients, a major obstacle in knowing which patient tumors have how much
drug and hence which patients are more likely to respond to treatment. Despite the
multifactorial nature of platinum resistance, reduced intracellular drug accumulation is
one of the most consistently identified features of Cisplatin-resistant cell lines [2-4],
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including resistant NSCLC cell lines [5-10]. More recently, a recent clinical study
established a relationship between tissue platinum concentration and response in NSCLC,
which suggests that reduced platinum accumulation might be an important mechanism of
platinum resistance in the clinical setting [11]. The use of radio labeled drug candidates
and PET/SPECT imaging, in early drug development, provides unique information that
bridges the gap between molecular biology, pharmacology, pathology and the design of
new generation therapeutic strategies and drug systems. For example, by labeling a
chemotherapeutic ([18F)-Paclitaxel) agent with a positron emitting radionuclide and by
monitoring the kinetics of the radioactivity in the tumor, in vivo chemoresistance have
been studied [12, 13]. Two approaches of radiolabeling platinum drugs; one using Pt
isotopes to synthesize drug and the other using 13N to label cisplatin have been published.
Baer et al [14] described the microscale synthesis of various platinum compounds labeled
with

191

Pt. Leal et al [15] established the production of radioactive cisplatin with and

without a cadmium capsule by irradiating cisplatin with thermal and epithermal neutrons
flux. This approach irradiates an intact drug to convert stable Pt to radioactive Pt.
However, this approach could produce radiation induced damage to the chemical
structure of the compound. Speigeleer et al [16] developed a microscale synthesis of
labeling cisplatin with cyclotron produced [13N]. Areberg et al [17] synthesized cisplatin
using

191

Pt,

193m

Pt, and

195m

Pt and calculated the absorbed doses to various organs and

tissues as well as effective doses from the radionuclides after administration to humans.
Thus, significant research efforts so far, to improve the overall efficacy of platinum-based
therapy in solid tumors, have all emphasized the need to know the most important factors
related to response: accumulation and retention of drug in tumors in a heterogeneous
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tumor, which is affected by a unique microenvironment such as tumor hypoxia. In light
of this, this research project aims to better utilize and update on the present therapeutic
norm of platinum-based anticancer therapy and this has led us to develop and evaluate a
[18F]-FCP, by introducing a molecular imaging entity [18F]-labeled malonic acid
coordinated to the drug which enables, through non-invasive PET imaging, quantitative
measurement of drug concentration in multiple tumors and normal tissues within an
individual patient. The rest of this chapter details the approach and methodologies
developed for the radiosynthesis of 19F-FCP and [18F]-FCP including in vitro, ex vivo and
in vivo imaging studies.

5.2

Experimental Section

5.2.1 Materials
All reagents and solvents were purchased from Sigma-Aldrich and used without further
purification unless otherwise indicated. All cold reactions were performed under argon
atmosphere in oven-dried glassware. Flash chromatography was performed employing
Sigma-Aldrich 230-400 mesh60 Å silica gel. TLC (Sigma-Aldrich, Saint Louis, MO) was
performed using silica gel-coated aluminum plates with F-254 indicator (250 mm, 20
cm20 cm, Whatman). NMR (Piscataway, NJ) spectra (1H-NMR, 13C-NMR, and

19

F-

NMR, 195Pt-NMR) were obtained using Varian Mercury 300 MHz and Varian Inova 400
MHz (Sigma-Aldrich, Saint Louis, MO) using tetramethylsilane as an internal standard.
Aqueous [18F]-fluoride was produced by the

18

O (p,n)18F reaction, in a PET tracer

cyclotron (GEMedical Systems, Wausheka, WI, USA), by the irradiation of an
isotopically enriched 98% [18O] water (Rotem Industries, Ber Sheva, Israel) target. For
fluoride trapping, Sep-Pak Light quaternary methyl ammonium (QMA) cartridge was
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used in manual synthesis from Waters Corp. (Milford, MA, USA). Radio-HPLC analysis
was carried using a Waters HPLC pump (Waters, Model 1525) equipped with UV
detector (Waters, Model 2489) and radiation detector (Bio-scan, Model B-FC-3300)
connected in series. For reverse phase HPLC, a Waters® Nova-Pak 4µ C18 150 x 3.9
mm column was eluted isocratically with 25/75 ACN/Water containing 0.1%TFA at flow
rate of 1 mL/min. Radio-TLC was performed on a radio-TLC scanner (BioScan, Model
AR/2000). Radioactivity was measured with dose calibrator Captintec CRC-15 PET.
Gamma counting was measured by gamma counter (Gamma counter (LKB Wallac 1282
compugamma CS universal gamma counter/Perkin Elmer). Animals, normal adult
athymic female nude mice, were purchased from Harlan laboratories, USA.

5.2.2 Synthesis of Cold Reference (19F-FCP)

5.2.2.1 Diethyl 2-(5-bromopentyl)-2-methylmalonate (1)
A solution of diethyl methylmalonate (6.0 g, 34.5 mmol) in dry dimethylformamide (50
mL) was treated portion wise with sodium hydride (1.5 g of a 60% dispersion, w/w, in
mineral oil, 38 mmol) with cooling. The reaction mixture was stirred for 30 min at
ambient temperature and treated with 1,5-dibrompentane (11.9 g, 51.8 mmol). The
reaction mixture was heated at 50 °C overnight and quenched by adding 30% ammonium
hydroxide solution. Distilled water (50 mL) was added in to the reaction mixture and
extracted with dichloromethane (3 x 50 mL). The organic layer was washed with brine,
dried over anhydrous sodium sulfate and concentrated under reduced pressure. The
residue was purified by flash chromatography using 5% ethyl acetate in hexane to give
alkyl malonate 1 as colorless viscous oil (8.0 g, 72%) (Scheme 1.): 1H-NMR (300 MHz)
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(CDCl3)  1.20 -1.33 (m, 2H), 1.25 (t, J = 7.32 Hz, 6H), 1.40 (s, 3H), 1.42 — 1.51(m,
2H), 1.81 — 191 (m, 4H), 3.39 (t, J = 6.73 Hz, 2H), 4.17 (q, J = 7.32 Hz, 4H); 13C-NMR
(75 MHz) (CDCl3)  13.9, 19.7, 23.3, 28.2, 32.3, 33.4, 35.1,53.4, 60.9, 172.1; ESI-MS
[M+Na]+m/z calcd for C13H23BrO4+Na 345.07 found 345.08.(NMR Fig 1)
5.2.2.2 Diethyl 2-methyl-2-(5-(tosyloxy)pentyl)malonate (2)
To a solution of alkyl malonate 1 (3.2 g 10 mmol) in dry acetonitrile (30 mL), silver
tosylate (3.48 g, 12.5 mmol) was added. After the reaction mixture was refluxed for 24 h
under an argon atmosphere, the reaction mixture was filtered through celite to remove the
silver salt and solvent was evaporated under reduced pressure. The residue obtained from
the solvent evaporation was purified by flash chromatography using 10% ethyl acetate in
hexane to give tosylate precursor 2 as a colorless viscous oil (3.9 g, 96%): 1H-NMR (300
MHz) (CDCl3)  1.18 — 1.25 (m, 2H), 1.23 (t, J = 7.22 Hz, 6H), 1.26 — 1.35 (m, 2H),
1.36 (s, 3H), 1.61 – 1.68 (m, 2H), 1.77 — 1.81 (m, 2H), 2.45 (s, 3H), 4.00 (t, J = 6.44 Hz,
2H), 4.16 (q, J = 7.22 Hz, 4H), 7.35 (d, J = 8.19 Hz, 2H) 7.78 (d, J = 8.19 Hz, 2H); 13CNMR (75 MHz) (CDCl3)  13.7, 19.4, 21.1, 23.2, 25.2, 28.1, 34.8, 53.1, 60.7, 70.1, 127.4,
129.6, 132.8, 144.4, 171.7; ESI-MS [M+Na]+m/z calcd for C13H23BrO4+Na 437.16
found 437.43.(NMR Fig 2)

5.2.2.3 Diethyl 2-(5-fluoropentyl)-2-methylmalonate (3)
To a solution of tosylate 2 (2.1 g, 5 mmol) in dry THF (20 mL), a solution
tetrabutylammonium fluoride TBAF (1 M solution in THF, 1.58 g, 6 mL, 6 mmol) was
added dropwise under argon atmosphere. The reaction mixture was stirred at 60 °C for 3
h. The reaction mixture was cooled to room temperature and solvent was evaporated
under reduced pressure. The product obtained from the solvent evaporation was purified
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by flash chromatography using 10% ethyl acetate in hexane to give fluoropentyl malonate
3 as a light yellow colored viscous oil (1.1 g, 84%): 1H-NMR (300 MHz) (CDCl3)  1.24
(t, J = 7.32 Hz, 6H), 1.25 -1.34 (m, 2H), 1.40 (s, 3H), 1.36 — 1.48 (m, 2H), 1.61 — 1.78
(m, 2H), 1.83 — 1.89 (m, 2H), 4.17 (q, J = 7.32 Hz, 4H), 4.34 (t, J = 6.15 Hz, 1H), 4.50 (t,
J = 6.15 Hz, 1H); 13C-NMR (75 MHz) (CDCl3)  13.87, 19.66, 23.79, 25.33, 25.40, 29.89,
30.15, 35.25, 53.43, 60.92, 82.49, 84.68, 172.12; ESI-MS [M+Na]+m/z calcd for
C13H23FO4+Na 285.15 was found 285.31. (NMR Fig 3, 4)
5.2.2.4 2-(5-Fluoropentyl)-2-methylmalonic acid (4)
To a stirred solution of fluoropentyl malonate 3 (310 mg, 1.5 mmol) in THF:MeOH:H2O
(6:3:1, 15 mL) was added lithium hydroxide monohydrate (631 mg, 15 mmol). The
reaction mixture was stirred 24 hr at room temperature. After the reaction was complete,
the organic solvents were removed under reduced pressure. The aqueous layer was
acidified with oxalic acid solution (1 mol) to pH 2-3 and then extracted with diethyl ether
(3 x 25 mL). The combined organic layers were dried over anhydrous sodium sulfate and
then concentrated under reduced pressure. The residue was dissolved in chloroform,
undissolved residue was filtered and the filtrate was concentrated under reduced pressure
to give reference compound ([19F]-FPMA) 4 (208 mg, 86%) as a white solid: mp = 102104 °C: 1H-NMR (300 MHz) (CDCl3)  1.32-1.47 (m, 4H), 1.49 (s, 3H), 1.65-1.78 (m,
2H), 1.90-1.94 (m, 2H), 4.37 (t, J = 6.05 Hz, 1H), 4.49 (t, J = 6.05 Hz, 1H) 10.48 (s, 2H);
C-NMR (75 MHz) (CDCl3)  20.09, 24.22, 25.59, 25.66, 30.14, 30.40, 35.63, 54.03,

13

83.04, 85.22, 178.43;

F-NMR (300 MHz) (CDCl3) (coupled)  -218.88 (m); ESI-MS

19

[M+Na]+m/z calcd for C9H15FO4+Na 229.09 found 229.09. 1H-NMR, spectra is shown
in NMR Fig 5,6.
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5.2.2.5 Non-radioactive Reference Compound 19F-FCP
Cisplatin 50 mg and silver nitrate 50 mg was dissolved in nanopure water (2.5 mL) and
reaction was stirred at room temperature for overnight in protected light. After filtration
of the precipitated silver chloride, one equivalent 2-(5-Fluoropentyl)-2-methylmalonic
acid (4) was added, and the mixture was stirred at room temperature for 2 days. Product
was purified by Sep-Pak purification method using water as eluent. Finally, water
fraction was lyophilized to give fluorinated carboplatin drug. Analysis of Carboplatin
Derivative 1H-NMR (300 MHz) (D2O) δ 1.32-1.47 (m, 4H), 1.49 (s, 3H), 1.65-1.78 (m,
2H), 1.90-1.94 (m, 2H), 4.50 (t, J = 6.05 Hz, 1H), 4.66 (t, J = 6.05 Hz, 1H) ; 19F-NMR
(300 MHz) (D2O) δ -218.88 (m);:195Pt-NMR (300 MHz) (D2O) δ -1596 (broad
singlet).(NMR Fig 7)

5.2.3 Manual Synthesis and Characterization of [18F]-FCP
Radiosynthesis of [18F]-FPMA was carried out using the tosylate precursor. [18F] Fluoride
was produced by the

18

O (p,n)18F reaction in a PETtrace cyclotron by the irradiation of

an isotopically enriched [18O] water target using a 16 MeV proton beam. [18F] Fluoride
was then passed through a QMA Sep-Pak that was preconditioned with (0.25 mol)
potassium carbonate solution followed by sterile water. The trapped [18F] Fluoride was
eluted with a solution having 0.08 mL of potassium carbonate (0.25 mol) and 0.42 mL of
sterile water into 10 mL V vial containing a solution of Kryptofix (12 mg) in dry
acetonitrile (0.8 mL). The reaction mixture was dried with the addition of dry acetonitrile
at 80 °C. After drying 4 mg tosylate precursor in acetonitrile (0.8 mL) was added and the
reaction heated at 110 °C for 10 min. The reaction mixture was cooled for 5 min and then
solvent evaporated under vacuum and helium flow room temperature. Base hydrolysis
was accomplished by the addition of methanolic NaOH solution in 2 mL of
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(DCM:MeOH; 9:1) for 20 min at 45 °C. After solvent evaporation sodium citrate buffer
(pH 3) and 3 mol HCl (1.5:0.5 mL) was added. The reaction mixture was passed through
a preconditioned C18 column and eluted with 2 mL ethanol. The ethanol was evaporated
at 45°C under vacuum and helium flow. The final [18F]-FPMA was redissolved in water
and aqua platinum complex was added to the activity vial at 75 °C for 30 min. In the
reaction some of the unreacted starting compound, [18F]-FPMA was observed by HPLC
analysis. Final [18F]-carboplatin derivative was purified by QMA Sep-Pak ion-exchange
cartridge.

5.2.4 Automated Synthesis and Characterization of [18F]-FCP
Encouraged by the feasibility of manual synthesis of [18F]-FCP, we initiated the
development of automated synthesis of [18F]-FCP. Automation provides benefits of
reduced duration of synthesis, reduced waste, reproducibility and scaled up reaction
without personnel exposure.
Automated radiosynthesis of [18F]-FCP was carried out on Allinone Synthesizer (Trasis,
Belgium) (Fig. 17) via [18F]-FPMA route as shown in the Scheme 2. Briefly, initial
optimization of automated radiosynthesis [18F]-FPMA and purification was carried out on
Allinone Synthesizer based on earlier manual radiosynthesis. Radiochemical yield (RCY)
and radiochemical purity (RCP) was confirmed by radio-HPLC. The radiosynthesis
procedure for [18F]-FCP was a three step reaction process. Each step was programmed as
a sequence with appropriate macros in the automated synthesizer. Each sequence was
optimized along the reaction progression to produce a final product, [18F]-FCP, with high
radiochemical yield.
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Briefly, the manual synthetic procedure involves the synthesis of platinum aqua complex
ahead of the reaction. The pre-made platinum aqua complex was placed in Allinone
Synthesizer in a closed vial under nitrogen protection. After purification and evaporation
of ethanol solvent from [18F]-FPMA, it was incubated with platinum aqua complex at
82°C for 30 mins to yield [18F]-FCP. Final [18F]-FCP was characterized and
radiochemical purity (RCP) was confirmed by radio-HPLC.

Figure 17: Automated synthesis of [18F]-FCP using AllInone Synthesizer. The cassette for the three
step reaction was prepared using manifolds. Machine test was performed to verify the optimal
vacuum, pressure and the movement of all components before placing the manifold in the synthesizer
as shown above. After the placement of the cassette, the cassette test was performed to test the leak,
vacuum in the reactor vials and the syringe positions. After all the tests were successful, reagent vials
were placed as shown above and the pre programmed sequences for the synthesis was started for the
complete synthesis procedure.
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5.2.5 Cell Lines and Culture Conditions
All cell lines were maintained in humidified incubator at 37 °C and 5% CO2. Human
Cervical Adenocarcinoma (KB 3-1 and KB 8-5) were purchased from National Institute
of Health (NIH). Lung Carcinoma (A549), Ovarian Carcinoma (SK-OV-3), Colorectal
Carcinoma (COLO-205), Renal Carcinoma (A498) and Prostate Carcinoma (LNCap) was
purchased from ATCC. Head and Neck Carcinoma (FaDu) cell line was a gift from Dr.
Andrei Pugachev at Virginia Commonwealth Massey Cancer Center. Briefly, KB-3-1 and
KB 8-5 cells were grown in DMEM/High glucose medium supplemented with 10% fetal
bovine serum (FBS), 5mM L-Glutamine, Penicillin (100U/ml), Streptomycin (100µg/ml)
and Amphotericin B (0.25 ug/ml). KB-8-5 cell lines were grown in similar media
supplemented further with 10ng/ml colchicine. COLO-205, FaDu, A498, LNCap cells
were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS
Penicillin G (100U/ml), Streptomycin (100µg/ml) and Amphotericin B (0.25 ug/ml). The
cells were grown to 70-80% confluency before using for the experiments.

5.2.6 Tumor Xenograft/Animal Model
KB-3-1 and KB 8-5 cells were maintained in DMEM/High glucose medium
supplemented with 10% fetal bovine serum (FBS), 5mM L-Glutamine, Penicillin
(100U/ml), Streptomycin (100µg/ml) and Amphotericin B (0.25 ug/ml).
Female athymic nude mice, (4-6 weeks old, weight: 18-25 g) were purchased from
Harlan laboratories, USA and provided with food and water ad libitum. Animal
experiments were approved and performed according to the policies and guidelines of the
Animal Care and Use Committee (IACUC) at Virginia Commonwealth University. KB3-1 and KB-8-5 cells were cultured as mentioned above and collected for implantation.
Tumor cells 2.5×106/100µL (KB 3-1), 2.5.0×106/100µL (KB 8-5) in media without
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serum) were injected subcutaneously into the dorsal region on the right shoulder (KB8-5)
and left (KB 3-1) shoulder of athymic nude mice. Following subcutaneous implantation
digital caliper measurement of tumor size was accessed, once the bulge caused by the
tumor growth at the injection site was visible, (approximately 5 days). The tumor volume
was calculated using the formula 0.523 × (length × width × thickness) and assessed thrice
per week.

5.2.7 In vitro Cytotoxicity of 19F-FCP
The cytotoxicity of

19

F-FCP was compared with cisplatin and carboplatin by incubating

in various cell lines. The cell viability of COLO-205, SK-OV-3, FaDu, A549, A498,
LNCaP, RWPE-1 and KB-3-1 cells treated with cis-platinum and carboplatin, and
fluorinated carboplatin was evaluated using Cell Titer Glo assay kit (Promega, USA).
Briefly, depending on the cell type, 3,000 to 4000 cells in 25 µl complete media were
plated in opaque 384-well plate in triplicates for each cell type and cultured overnight in
the incubator. The next day the cells were treated with 25 µl drug for final concentrations
from 0.001 (µM) to 100 (µM) for 72 hrs and 96 hrs. At the end of incubation period 50 µl
assay reagent was added to each well, and the cell viability was assessed by measuring
the luminescence, detected by a plate reader (Beckman Coulter). The luminescence
detected in untreated cells was used as control (100% Viability) to calculate percent
viability in each treatment groups. Statistical analysis was done using Student’s t-test and
the p value calculated based on two-tailed test using Microsoft Excel software. P<0.05
was considered statistically significant.
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5.2.8 Biodistribution and in vivo Stability Analysis
Animal experiments were approved and performed according to the policies and
guidelines of the Animal Care and Use Committee at Virginia Commonwealth University.
The biodistribution of [18F]-FCP was measured in normal adult female nude mice
(Harlan). Under 2% isoflurane, three group of three mice received an intravenous
injection (tail vein) of [18F]-FCP (1.5-2MBq, in 200µL PBS, at the start of the
experiment). Under anesthesia, mice were sacrificed by cervical dislocation at 5, 30, and
90 mins post injection. Whole blood was collected by cardiac puncture, other major
organs were harvested and weighed, and the radioactivity in the organs/tissues was
counted in a gamma counter (Gamma counter (LKB Wallac 1282 compugamma CS
universal gamma counter/Perkin Elmer). The blood activity was used to calculate the
blood half life. Decay-corrected radiotracer uptake in each tissue at various time points
was then calculated as the percent injected dose per gram of tissue (%ID/g).
In vivo stability of [18F]-FCP in plasma and urine was determined following radiotracer
administration in normal female nude mice under 2% isoflurane anesthesia. Samples
were collected at 5, 30, 60, and 90 minutes following intravenous injection of [18F]-FCP.
The collected samples of plasma were centrifuged for 10 mins at 10,000g. Supernatant
from these samples was filtered through 0.2µ filter and 200µL plasma supernatant was
injected into reversed-phase HPLC (column Waters Nova-Pak 4 µ C18 150× 3.9 mm,
CH3CN/H2O 25:75, containing 0.1% TFA at flow rate 1mL/min). Urine samples were
also filtered and analyzed in the same HPLC system.
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5.2.9 PET Imaging Studies
Small animal PET/CT imaging studies were performed using a Siemens Inveon®
Multimodality PET/CT system (Siemens Medical Solutions Inc., Knoxville, TN, USA). Ten
minutes prior to imaging, the animals were anesthetized using 2% isoflurane at room
temperature until stable vital signs were established. Once the animal was sedated, the animal
was placed onto the imaging bed under mixtures of O2 (1 mL/min) and 2% isoflurane for
the duration of the imaging. [18F]-FCP (5.5-6 MBq/200 µL) was injected intravenously in a
normal female nude mouse via the tail vein. Immediately following the injection, a 90 minute
dynamic scan was performed.
Nude mice were innoculated with human cervical adenocarcinoma (KB) cell lines to
establish a xenograft model with one P-glycoprotein (P-gp) non expressing (KB 3-1) and one
Pgp

expressing (KB 8-5) tumor per animal. [18F]-FCP formulation (5.5-6 MBq) was

injected intravenously in xenograft nude mice via tail vein injection. Static summed up image
data acquired 60 minutes post injection was acquired for 30 mins. The micro CT imaging was
acquired following the PET imaging at 80kV and 500μA with a focal spot of 58μm.

PET images were reconstructed using Fourier Re-binning and Ordered Subsets
Expectation Maximization (OSEM) 3D algorithm with dynamic framing every 60
seconds. Reconstructed images were fused and analyzed using Inveon® Research
Workplace (IRW) software. For quantitation, regions of interest were placed in the areas
expressing the highest radiotracer activity as determined by visual inspection. The
resulting quantitative data were expressed in Percent Injected Dose per Gram (%ID/g).

5.2.10 Protein Extraction and Western Blot
The KB-3-1 and KB-8-5 tumors were excised from the tumor bearing mice, snap frozen
in liquid nitrogen and stored in -800C until further use. Approximately 80-100 mg of
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tumor was excised and homogenized in 500 µLof lysis buffer (Pierce RIPA buffer)
containing protease inhibitor (PI) (Halt protease inhibitor, Pierce) and EDTA (Pierce) in a
hand held homogenizer on ice. The tumor lysate was collected and stored in -800C. KB3-1 and KB-8-5 cells were also collected and lysed in lysis buffer containing PI/DETA.
The homogenate/cell lysate were spun down at 12,000 rpm for 15 min and the clear
supernatant was collected for protein assay. The amount of protein in -supernatant was
estimated using BCA Protein assay kit (Pierce/Thermo scientific). Twenty µg of protein
was resolved on 7.5% tris-glycine gel. The proteins were transferred onto PVDF
membrane, at 100V for 1hr. To prevent non-specific binding of the antibody, the PVDF
membrane was blocked with Odyssey blocking buffer (Cat No; 927-40000, LiCor) for 1
hr at room temperature (R.T). The blots were the incubated overnight at 40C with primary
antibodies, anti-P Glycoprotein antibody (F4) Cat No: ab80594 and rabbit β-actin mAb
(Cell signaling, Cat No 4970) respectively. After washing the blot with PBS/0.1%
Tween-20, for four times , the blot was incubated with secondary antibodies, IRDye
680LT Goat anti-mouse IgG and IRDye 800CW Goat anti-rabbit IgG (Li-Cor)
respectively. The blot was rinsed in wash buffer and the bands for P-gp and β-actin on
PVDF membrane was detected using Odyssey CLx. The image was analyzed and
quantified using Image Studio 2.0 software.

5.3

Results

5.3.1 Synthesis of 19F-FCP
Scheme 1 describes the synthesis of the tosylated precursor and reference standard
compound [19F] 2-(5-fluoro-pentyl)-2-methylmalonic acid (4). The reference nonradioactive compound 5 was synthesized in four steps starting with commercially
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available diethyl methylmalonate. Diethyl methylmalonate was alkylated with 1,5dibromopentane in presence of NaH to give alkylated compound 1 in 72% yield using the
procedure of Astles et al. Excess 1,5-dibromopentane was used to avoid disubstitution.
The bromide was displaced using commercially available silver tosylate to give a
tosylated precursor 2 in 96% yield. The tosylate group was exchanged for the required
fluoride by a nucleophilic displacement reaction using tetrabutylammonium fluoride
(TBAF) to give diethyl 2-(5-fluoropentyl)-2-methyl malonate 3 in 84% yield.
Fluoropentyl diethyl malonate ester 3 was hydrolyzed using lithium hydroxide under
mild conditions to give 2-(5-fluoro-pentyl)-2-methyl malonic acid as a white solid with
50% overall yield. Finally, 2-(5-fluoro-pentyl)-2-methyl malonic acid 4 was incubated
with platinum aqua complex for 2 days to give F-19 Carboplatin derivative 5. All the
intermediate compounds and final compound were fully characterized by 1H-NMR, 13CNMR, 19F-NMR, and ESI-MS analysis. Fluorination of compound 3 was confirmed by
19

F-NMR, which showed the expected multiplet pattern and had a chemical shift in the

expected region (218.88 for terminal (CH2F)). The calculated molecular mass for purified
2- (5-fluoro-pentyl)-2-methyl malonic acid was in agreement with experimental value.
Chemical purity was found to be greater than 98% as determined by analytical HPLC.
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Scheme 1: Synthesis of cold reference compound 19F-FCP and tosylate precursor of 19F-FCP. Reagents
and conditions: (a) 1,5-dibromopentane, NaH,DMF, 50 ºC, 12 h, 72%; (b) silver tosylate, ACN, reflux, 12
h, 96%; (c) TBAF, THF,60 ºC, 3 h, 84%; (d) LiOH/H2O THF/MeOH/H2O (6:3:1), rt, 24 h, 86% (e)
platinum aqua complex, rt, 2 days.

5.3.2 In vitro Cytotoxicity of 19F-FCP
A key prerequisite for a drug analog is that it must not alter the anti-tumor activity of the
parent drug. To directly compare the cytotoxicity of

19

F-FCP with cisplatin and

carboplatin, in vitro a panel of eight cell lines of different origin; COLO 205, SK-OV-3,
FaDu, A549, A498, LNCaP, RWPE-1 and KB-3-1, was treated with

19

F-FCP with

cisplatin and carboplatin at concentrations from 0.001 (µM) to 100 (µM) for 72 hrs and
96 hrs. At the end of the incubation period, the percent viable cells were evaluated by
measuring amount of ATP released from viable cells using Cell Titer-Glo reagent. The
percent viability of each cell line at various concentrations of drugs was plotted and used
to calculate the IC50 for each drug. Table 9 reports IC50 (50% growth inhibition
concentration) values for each of the eight cell lines. Different cell lines exhibited
different sensitivities to platinum compounds depending on their origins, morphologies,
and tumorigenicites. Based on the cell viability data, the IC50 values for the various
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platinum compounds demonstrated that cisplatin reduced the cell viability to the greater
extent than carboplatin, and

19

F-FCP. The cytotoxicity of

19

F-FCP was slightly higher

than carboplatin suggesting that 19F-FCP is more potent than carboplatin. Cytotoxic effect
for all three compounds was time dependent. Increasing the incubation time from 72
hours to 96 hours reduced the IC50 values for all three compounds indicating that the
cytotoxic activity of all three compounds was elevated with time.

Table 9: IC50 values of cisplatin, carboplatin and 19F-FCP in various cancer cell lines

5.3.3 Radiosynthesis of [18F]-FCP
Scheme 2 represents manual and automated radiosynthesis of [18F] 2-(5-fluoropentyl)-2methyl malonic acid ([18F]-FPMA) in two steps: (i) Kryptofix-mediated direct
nucleophilic fluorination and (ii) NaOH base hydrolysis (iii) conjugation with platinumaqua complex.
Radiofluorination of 2 was carried out in the presence of Kryptofix and K2CO3 in
acetonitrile, optimum conditions of 8-mg precursor, 110 ºC, and 20 min. reaction time
resulted in >90% RCY of non-hydrolyzed compound 6 as confirmed by radio-thin-layer
chromatography (TLC) analysis. After radiolabeling, the acetonitrile was evaporated with
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helium flow under vacuum, and the product was subjected to base hydrolysis. Complete
hydrolysis was achieved by methanolic sodium hydroxide (3 M) in dichloromethane
(DCM)/methanol (9:1) for 20 min at 45 ºC. The final product was purified by solid phase
extraction. After evaporation of the solvent, under vacuum and helium flow, the product
was re-dissolved in water and adjusted to pH 2–3 using 3 M HCl. The reaction mixture
was passed through a C18 Sep-Pak column, and the column was washed with 10 mL of
water to remove free fluoride and byproducts of para-toluene sulphonic acid. The
product was eluted with multiple 0.5 mL ethanol fractions. Greater than 90% of product
radioactivity was eluted in fractions 3 and 4. The overall decay-corrected (yield of 7, 50
min after introduction of [18F]-fluoride activity) isolated RCY of [18F]-FPMA was 60%,
and the radiochemical purity (RCP) was more than 98% in 50 min total synthesis time.
RCP was confirmed by radio-HPLC. Co-injections with non-radioactive fluorinated
compound gave the same retention time as [18F]-FPMA = 4 min. Compound 7 was
completely dried under helium flow under vacuum. Aqua platinum complex was added to
the reaction vial 7 for further conjugation at 80 ºC for 30 mins to yield the final
compound. The final product 8 was purified by QMA anion exchange column. The
product was eluted with multiple 0.5 mL water fractions. The decay corrected (yield of
final product, 180 mins after the introduction of [18F]-fluoride activity isolated RCY of
[18F)-FCP was 14.3±3.8% (n=3), and the radiochemical purity was more than 98% in 180
mins synthesis time. RCP was confirmed by radio-HPLC (Fig 17). Retention time of
[18F)-FCP was 1.43 mins (Fig. 18).
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Scheme 2: Synthesis of [18F]-FCP. Reagents and conditions: (a) K18F/K222, K2CO3, ACN, 110 _C, 10
min condition used for manual synthesis; (b) glass microfluidic device,K18F/K222, K2CO3, ACN, 190 ºC,
condition used in automated microfluidic synthesis; (c) 3 mol NaOH, DCM/MeOH (9:1), 45ºC, 20 min; (d)
3 M HCl, in manual and sodium citrate buffer (pH 2.79) in microfluidic synthesis, was used for pH
adjustment (pH 2–3), (e) platinum aqua complex, 82 ºC, 30 mins.

Figure 18: Sample was run on Waters® 4µ C18 150 x 3.9 mm column; ACN/Water (0.1%TFA) 25/75
with flow rate of 1mL/min; Fig A. RT = 3.38 min. of Radioactivity [18F]-FPMA; Fig B: HPLC profile
of Platinum coordination reaction; Fig. C: HPLC profile after purification RT=1.43 min of [18F]-FCP.
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5.3.4 Biodistribution and in vivo Stability Analysis
Table 10 and Fig.19 show the biodistribution of [18F]-FCP in female nude mice. The
radiotracer demonstrated rapid blood clearance with less than 2% of radioactivity
remaining in the circulation after 1 h. The blood half life was calculated to be 10-12 mins.
Most organs showed low accumulation of the radiotracer and radioactivity was
predominantly cleared through the kidneys with greater than 95% cleared 1 h after
injection.
The in vivo stability of [18F]-FCP in plasma and urine was assessed during the first 60
mins after intravenous administration in normal nude mice. The stability of [ 18F]-FCP
was analyzed by radio-HPLC at 5, 30, 60, and 90 mins post administration. The radio
HPLC peak of the plasma samples injected appeared at the same retention time as the
initial injected radiotracer (Fig. 20), demonstrating an intact [18F]-FCP 60 min-post
injection. No radioactivity was detected in 90 min samples which could be attributed to
the fast physiological clearance of the radiotracer from the blood. The radio HPLC peak
of the urine samples injected also appeared at the same retention time as the initial
injected radiotracer demonstrating the intact [18F]-FCP (data not shown).
Table 10: Biodistribution of intravenously injected [18F]-FCP in nude mice (n=3 per time point).
Data are presented as %ID/g (mean±sem) values determined through gamma counting

Organs
Blood
Heart
Lungs
Liver
Spleen
Stomach
Intestine
Kidneys
Skin
Muscle
Brain

5 Mins
4.56±0.67
1.5±0.09
3.20±0.018
4.54±0.50
1.43±0.50
1.36±0.37
2.84±0.31
10.47±2.77
4.40±0.70
2.56±0.73
0.22±0.01

30 Mins
1.09±0.62
0.62±0.36
1.27±0.73
3.48±2.01
0.91±0.53
0.75±0.43
2.28±1.31
4.98±2.88
1.30±0.75
0.69±0.40
0.10±0.06

90 Mins
0.99±0.57
0.71±0.41
1.37±0.79
2.28±1.31
1.70±0.98
0.38±0.22
1.65±0.95
4.63±2.67
1.13±0.65
0.678±0.38
0.12±0.072
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Femur

1.02±0.17

0.78±0.45

0.53±0.30

Figure 19: Biodistribution of [18F]-FCP in normal adult female nude mice (n=3) at 5, 30, 90 mins
after injection. Radio tracer uptake in % ID/g was determined by gamma counting.

Figure 20: Plasma sample was run on Waters® 4µ C18 150 x 3.9 mm column; ACN/Water
(0.1%TFA) 25/75 with flow rate of 1mL/min at different time point; Fig. A: 05 min; Fig. B: 30 min;
Fig. C: 60 min.
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5.3.5 PET Imaging Studies
[18F]-FCP imaging in nude mice was performed to establish PET imaging feasibility and
biodistribution. Dynamic images acquired for 90 mins illustrate the full body distribution
of [18F]-FCP (Fig. 21). [18F]-FCP had the highest uptake in kidneys. Accumulation of
radiotracer was also seen in lungs and liver in early time points. High uptake in the
kidneys seems to reflect urinary excretion of the tracer which can be attributed to the
radioactivity present in the urine during the scan. Images showed the subsequent
clearance of radiotracer with time. Ex-vivo biodistribution data on the tissue distribution
correlated to the imaging data.

Figure 21: A female nude mouse was injected (i.v) with 5.5-6 MBq of [18F]-FCP derivative and
imaged using an Inveon PET/CT scanner (SIEMENS,USA). Dynamic image data acquired between 5,
30, 60 and 90 minutes post injection was reconstructed (FBP and OSEM/MAP) and analyzed.
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Static summed up images acquired 90 mins post radiotracer administration illustrate the
full body distribution of [18F]-FCP in tumor bearing mice (Fig. 22). Major uptake was
observed in liver and abdominal region. Quantification of the 90-min static summed up
scans of xenograft tumors (KB3-1 and KB 8-5) with ROI analysis showed differential
uptake of radiotracer in these tumors. Images showed a significant difference in uptake
between Pgp (+ve) and Pgp (-ve) tumor.

Figure 22: Nude mice were innoculated with human cervical adenocarcinoma (KB) cell lines to
establish a xenograft model with one P-glycoprotein (P-gp) non expressing (KB 3-1) and one Pgp
expressing (KB 8-5) tumor per animal. [18F]-FCP (5.5-6 MBq) was injected intravenously in
xenograft nude mice via tail vein injection. Imaging was carried out 90 mins post injection using
Inveon PET/CT (Siemens, USA). Static summed up image acquired 90 mins post injection was
reconstructed (FBP and OSEM3D/MAP) and analyzed. Image showed that P-gp non expressing (KB
3-1) tumor has slightly higher uptake of radiotracer than P-gp expressing KB 8-5 tumor.
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5.3.6 Protein expression and Western Blotting
The PET image of the KB-3-1 and KB-8-5 tumor bearing mice showed subtle difference
in the accumulation of [18F]-FCP. To determine whether this differences in the
accumulation was attributed to level of P-gp, tumors from the imaged mice were taken,
homogenized and immunoblotted against P-gp. As a loading control β-actin level in the
tumor were analyzed. The results after normalizing the signal of P-gp to β- actin showed
that the level of expression of P-gp in KB-8-5 tumor was twice compared with KB-3-1
tumor.

5.4 Discussion
One of the major hindrances in platinum therapy is the assessment between the amount of
drug administered, the amount of drug that reaches the targeted therapeutic site and
overall therapeutic efficacy of the treatment. Non-invasive studies of the tissue
concentrations are rare using radiolabeled platinum. Areberg et al [18] studied the
antitumor effect of radioactive cisplatin (191Pt) on nude mice and demonstrated that 191Ptcisplatin is a more effective drug than cisplatin in retarding tumor growth on tumor
growing nude mice. Patient studies by Areberg et al [17, 19] demonstrated the use of
radiolabeled with

191

Pt,

193m

Pt,

195m

Pt to visualize the uptake of platinum in tumors and

tissues non-invasively after cisplatin treatment. Dowell et al [20] used

195m

Pt labeled

cisplatin and carboplatin to estimate the amount of platinated drug and its metabolites at
the tumor site and at selected organs using noninvasive imaging. However, the major
problems with the known platinum radionuclides (191Pt, 193mPt, 195mPt, 197Pt) is the limited
supply of the highly enriched platinum isotope needed for the reactor production, and that
the cross sections needed for the production of platinum radionuclides from cyclotron is
not very favorable [20].
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This study demonstrated the feasibility of utilizing our previously published work on
[18F]-FPMA [21] in the synthesis of [18F]-FCP. Ease of production and well suited for
routine use of 18F in nuclear medicine application, 18F remains the radionuclide of choice
for PET/CT. In this project, we have presented the results of the radiosynthesis of [ 18F]FCP, a theranostic anticancer drug for imaging and therapy, and its feasibility of in vivo
imaging using PET in animal model. This project addressed a major need to enhance the
overall efficacy of platinum-based chemotherapy in solid tumors, by introducing F-18 as a
molecular PET imaging entity as part of the drug to enable the measurement of drug
concentration in tumors and normal tissues. An important finding of the study was the very

high stability of the drug in plasma and urine at 60 mins after administration (Fig 20).
Such stability ensures that the drug is intact in vivo and the radioactivity measured
throughout the study (in vivo imaging and ex vivo analysis) originates from the intact
drug instead of the potential metabolites.
[18F]-FCP exhibited uniform pattern of tissue uptake in tissues and tracer clearance
followed monoexponential blood kinetics. The blood half life is calculated to be 10-12
mins which is similar to the value presented in the literature for native carboplatin [22].
Following intravenous injection of [18F]-FCP in normal nude mice, quantification of the
dynamic images of the 90 mins, the highest activity was recorded in kidneys, bladder and
urine. Accumulation of [18F]-FCP was also recorded in liver and lungs in early time
points with subsequent clearance with time which is consistent with the findings by
Ginos et al [23]. Ex-vivo biodistribution data corresponded to the in-vivo findings with
major accumulation of radiotracer in kidneys and liver. In vitro cytotoxicity assay on
various cells lines demonstrated that 19F-FCP kills cancer cells with greater efficacy than
carboplatin.
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5.5 Conclusion
An automated radiosynthesis of 18F-FCP was developed, using our previously developed
18

F-FPMA radiotracer. In vivo data showed a rapid blood clearance and accelerated renal

elimination of intact radiotracer. Feasibility of non- invasive imaging and quantitation of
[18F]-FCP was demonstrated in normal and tumor bearing nude mice.
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NMR Fig 1: 1H-NMR and 13C-NMR of Diethyl 2-(5-bromopentyl)-2-methylmalonate
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NMR Fig 2

NMR Fig 2: 1H-NMR and 13C-NMR of Diethyl 2-methyl-2-(5-(tosyloxy)pentyl)malonate
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NMR Fig 3: 1H-NMR and 13C-NMR of Diethyl 2-(5-fluoropentyl)-2-methylmalonate
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NMR Fig4: 19F-NMR of Diethyl 2-(5-fluoropentyl)-2-methylmalonate
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NMR Fig 5: 1H-NMR and 13C-NMR 2-(5-Fluoropentyl)-2-methylmalonic acid
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NMR Fig 6: 19F-NMR of 2-(5-Fluoropentyl)-2-methylmalonic acid
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NMR Fig 7: 1H-NMR, 19F-NMR and 195Pt-NMR [F]-FCP
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CHAPTER 6: LIPOSOMAL CARBOPLATIN: A NOVEL
DOUBLE RADIOLABELED NANOCONSTRUCT FOR
DUAL TRACER IMAGING AND THERAPY
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6.1

Introduction

This chapter deals with the development of liposomal carboplatin formulation. This
chapter presents the development of [111In]-labeled Liposomes and its in vivo evaluation
in normal nude mice. Further, [18F]-FCP encapsulation of [111In]-labeled Liposomes to
develop a dual tracer labeled nanocarrier and its in vivo evaluation in two different tumor
xenograft bearing nude mice is also presented in this chapter.
Liposomes are self assembling vesicles composed of lipid bilayers and an enclosed
fraction of the surrounding aqueous medium [1]. Pharmacokinetics and distribution of
liposomes can be manipulated by modifying their size, charge, composition and surface
modification [2, 3]. Amenable surface modification, amphilphilic nature and
biodegradable properties of liposome make them an appealing vehicle for drug delivery.
Several attempts of radiolabeling liposomes using various isotopes have been tried for a
variety of reasons. The major aim of all of these studies using radiolabeled liposomes is
to follow the fate of liposome in vivo and to measure the distribution of the nanoparticles
quantitatively ex vivo. Information on the in vivo behavior of liposomes helps in
optimizing the liposome for novel imaging and therapeutic approaches.
Varieties of techniques have been developed to label liposomes with radioisotopes.
Radionuclides such as

99m

Tc,

186

Re,

67

Ga,

111

In were attached to the liposome using

chelators or by encapsulating them in aqueous cavity [4]. This project focuses on labeling
liposomes with

111

In. Diethylenetriaminepentaacetic acid (DTPA)-derivatized liposomes

have been widely used to radiolabel with

111

In [5]. Harrington et al [6] reported detailed

biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposome in nude
mice bearing a human cancer xenograft. Umeda et al [7] demonstrated the imaging ability
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of liposomes labeled with

67

Ga-NTA, and

111

In-NTA in various mouse tumor models.

Chow et al [8] compared the therapeutic effect of two different formulations of
vinorelbine encapsulated

111

In-Liposomes with varying concentration of polyethylene

glycol in human colorectal tumor bearing mice. Yang et al [9] evaluated the
pharmacokinetics of targeted and untargeted

111

In-doxorubicin liposomes in tumor

bearing mice in the presence of blood-brain barrier disruption. Mougin-Degraef et al [10]
designed liposomes with surface radiolabeled with

111

In- bound to DTPA lipid and the

aqueous phase labeled with 125I-Bolton Hunter-arginine for radioimmunotherapy. Presant
et al [11] applied Indium-111 labeled phospholipid vesicles to image variety of tumors in
vivo after intravenous administration in patients. Similarly, Kubo et al [12] determined
the radiation absorbed dose and tumor detection using Indium-111 labeled liposomes.
Liposome has wide range of properties that enables its use ranging from drug delivery to
imaging tumors.
This project focuses on designing [111In] -Labeled Liposome as a drug delivery vehicle
for [18F]-FCP. To our knowledge, there is no study on the synthesis and development of
carboplatin that combines

18

F as a molecular imaging entity. Furthermore, there is no

study that encapsulates [18F]-FCP inside [111In] -Labeled Liposome. Therefore, this
project is quite novel in determining the fate of both the drug and the vehicle in vivo
using non invasive multimodal imaging. This project develops a novel dual tracer labeled
liposomal nanocarrier as a multimodal imaging/therapy paradigm.
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6.2

Experimental

6.2.1 Chemicals
All chemicals were used as received without further purification. 1,2- dipalmitoyl-snglycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamineN-diethylenetriaminepentaacetic acid (ammonium salt) (DPPE-DTPA) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA). 1, 2-distearoyl-sn-glycero-3phosphoethanol-amine-N-[methoxy(polyethyleneglycol)-2000] ammonium salt (DSPEPEG2000) was bought from Laysan Bio, Inc. (Arab, AL, USA). Cholesterol (Chol), cisdiamminedichloridoplatinum (II) (Cisplatin), cis-Diammine(1,1cyclobutanedicarboxylato)platinum(II) (Carboplatin) were purchased from SigmaAldrich (Steinheim, Germany). Sephadex-G25 and all other materials were purchased
from VWR.
Flash chromatography was performed employing Sigma-Aldrich 230-400 mesh60 Å
silica gel. TLC (Sigma-Aldrich, Saint Louis, MO) was performed using silica gel-coated
aluminum plates with F-254 indicator (250 mm, 20 cm20 cm, Whatman). NMR
(Piscataway, NJ) spectra (1H-NMR, 13C-NMR, and 19F-NMR, 195Pt-NMR) were
obtained using Varian Mercury 300 MHz and Varian Inova 400 MHz (Sigma-Aldrich,
Saint Louis, MO) using tetramethylsilane as an internal standard. Aqueous [18F]-fluoride
was produced by the

18

O (p,n)18F reaction, in a PET tracer cyclotron (GEMedical

Systems, Wausheka, WI, USA), by the irradiation of an isotopically enriched [ 18O] water
(Rotem Industries, Ber Sheva, Israel) target. For fluoride trapping, Sep-Pak Light
quaternary methyl ammonium (QMA) cartridge was used in manual synthesis from
Waters Corp. (Milford, MA, USA). Radio-HPLC stability analysis was carried using a
Waters HPLC pump (Waters, Model 1525) equipped with UV detector (Waters, Model
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2489) and radiation detector (Bio-scan, Model B-FC-3300) connected in series. For
reverse phase HPLC, a Waters® Nova-Pak 4µ C18 150 x 3.9 mm column was eluted
isocratically with 25/75 ACN/Water containing 0.1%TFA at flow rate of 1 mL/min.
Radio-TLC was performed on a radio-TLC scanner (BioScan, Model AR/2000).
Radioactivity was measured with dose calibrator Captintec CRC-15 PET. Animals,
normal adult athymic female nude mice, were purchased from Harlan laboratories, USA.
111

In-indium chloride in 0.05M HCl (specific activity: 15.70mCi/mL) was purchased

from Perkin-Elmer (Wellesley, MA) and Triad Isotopes (Richmond, VA).

6.2.2 [111In]-Labeled Liposome Preparation
PEGylated liposome was synthesized using the method described my Mougin-degraef et
al [10]. Briefly DPPC, Chol, DSPE-PEG2000, DPPE-DTPA (60:30:5:5 mole ratio) were
mixed in a 10 ml vial and dissolved with Chloroform: Methanol (CHCl3:MeOH, 9:1).
The solvent was evaporated under rotary evaporator to form a lipid film followed by high
vacuum to remove the residual organic solvent. Dulbecco’s phosphate buffered saline
(PBS; 1ml) was added and the suspension was sonicated at 50-60ºC for 10 mins. At the
end of the incubation, the liposome solution was immediately chilled in ice. The resulting
vesicles were extruded through a series of polycarbonate membrane at 50-60ºC. The
extruded liposomes were purified using gel chromatography on Sephadex G-25 with PBS
as an eluent.

6.2.3 Labeling Procedure
PEGylated liposome was labeled with

111

In as previously described by Chow et al.[13].

Briefly, 500 µL of preformed liposome was incubated with 20 µL of

111

InCl3 (Indium

Chloride in 0.05 M HCl; 3.7–74 MBq) (Perkin Elmer/Triad Isotopes) in 20 µL of 3M

- 111 -

sodium acetate buffer (pH 5.2) and then incubated at 40ºC for 30 min. Unincorporated
111

In was purified using gel chromatography (Sephadex G-25). The labeling efficiency

was determined by measuring the activity in dose calibrator (CRC-15R, Capintec;
Bioscan) for the liposome, filter and supernatant.

6.2.4 Biodistribution of [111In]-Labeled Liposome:
Animal experiments were approved and performed according to the policies and
guidelines of the Animal Care and Use Committee (IACUC) at Virginia Commonwealth
University. Adult female nude mice were injected with
DTPA-DPPE, and

111

111

InCl3,

111

In-DTPA,

111

In-

In-Liposome through tail vein. The amount of radiotracer injected

was (1.07± 0.03 MBq) in 200 µL PBS. At different time points post injection (1hr, 6hrs,
48hrs), mice were euthanized and key tissues were harvested. Tissues were counted in
gamma counter and percent injected dose per gram (%ID/g) of the tissue was determined.

6.2.5 In vivo SPECT/CT Imaging of [111In]-Labeled Liposome
Micro-SPECT was performed using a multimodal (DPET/SPECT/CT) preclinical
imaging system (Siemens, USA) having dual-head camera mounted with 2 multipinhole
collimators (five 1.0-mm pinholes in each collimator, 51-mm trasaxial FOV, 40-mm
radius of rotation and maximum resolution of 1.5 mm). Images were acquired over 360o
in a total of 40 projections, resulting in a total imaging time of 30 min. Nude mice were
intravenously injected with with [111In]-Labeled Liposomes (8MBq, 200 μL) and 2, 48,
144 hrs later, were anesthetized with mixture of 2% isoflurane in oxygen and whole body
micro-SPECT imaging was carried out in prone position as described above. Micro-CT
was also performed with 75 kV and 500 μA at a resolution of 96 μm. The whole body
scan time was 10 min. The SPECT images were reconstructed using an iterative
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reconstruction algorithm (ordered-subset expectation maximization or OSEM3D)
modified for the 5-pinhole geometry with a 20% energy window around the 171 keV
photo peak of

111

In. These images were then registered with CT images based on a

transformation matrix previously generated using four

57

Co landmarkers. Images were

viewed and quantified using ASIpro, the image data analysis software. Regions of
interest (ROIs), covering the entire organs, were drawn and the average counts were
measured and the data was correlated to ex vivo biodistribution result from gamma
counting.

6.2.6 Synthesis of [18F]-FCP encapsulated [111In]-Labeled Liposomes
6.2.6.1 Synthesis of [18F]-FCP
[18F]-FCP was synthesized using an automated synthesis method using Allinone
Synthesizer (Trasis, Belgium) as described previously in section 5.2.4.

6.2.6.2 Labeled Liposome Preparation and Drug Loading
PEGylated liposome was synthesized using the method described by Mougin-degraef et
al[10]. Briefly, DPPC, Chol, DSPE-PEG2000, DPPE-DTPA (60:30:5:5 mole ratio) were
mixed in 10 ml vial and dissolved with Chloroform:Methanol (CHCl3:MeOH, 9:1). The
solvent was evaporated under rotary evaporator to form a lipid film followed by high
vacuum to remove the residual organic solvent. Freshly synthesized [18F]-FCP in PBS
was added to the lipid film and was sonicated for 10 min at 60ºC. At the end of
sonication, the liposome solution was immediately chilled in ice. For the membrane
radiolabeling with 111In, sodium acetate buffer (3M, pH 5.2) wad added to liposome
solution. 111InCl3 was buffered with sodium acetate buffer (3M, pH 5.2) for 2 mins before
incubating with buffered liposome solution at 40ºC for 30 mins. The resultant dual
labeled liposome nanoconstruct was purified using gel chromatography (Sephadex G- 113 -

25).The purified liposome nanoconstruct was further used for characterization and in vivo
studies.

6.2.6.3 Characterization
Zeta Sizer Nano Series ZEN3600 was used to measure the hydrodynamic size and ζ
potential of liposomes in PBS (pH~7.2). The radioactive reaction yield was calculated
from gamma counting. The labeling and encapsulation efficiency were determined by
counting the liposome suspension before and after chromatography on a PD-10
(Sephadex G-25) with a dose calibrator (CRC-15R, Capintec; Bioscan).

6.2. 6.4 In Vivo Dual Tracer Imaging with Trimodal PET/SPECT/CT
Female nude hairless mice (Harlan Laboratories, USA), aged four-six weeks, innoculated
with KB 3-1 and COLO 205 on dorsal regions on left shoulder and right flank
respectively were employed for the in vivo imaging. [18F]-FCP encapsulated [111In]Labeled Liposome was administered via tail vein injection. Each mouse was injected
with total activity of 15MBq of [18F]-FCP encapsulated [111In]-Labeled Liposome. One
hour post administration, mice were anesthetized by Isoflurane (2.0% flow rate) and kept
under nose cone set up for imaging. Static summed up PET image data 60 minutes post
injection was acquired for 30 mins. At completion of the PET imaging, without moving the
specimen, the mouse bed was moved to the SPECT/CT imaging planes. A SPECT scan was

performed using dual-head camera mounted with 2 multipinhole collimators (five 1.0mm pinholes in each collimator, 51-mm trasaxial FOV, 40-mm radius of rotation and
maximum resolution of 1.5 mm). Images were acquired over 360o in a total of 40
projections, resulting in a total imaging time of 60 mins. Micro-CT was also performed
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with 75 kV and 500 μA at a resolution of 96 μm. The whole body scan time was 10 min
(Fig. 23).
After the scan, the mice were returned to the cage. The same mice were SPECT scanned
24, 48 and 72 hours post administration.

Figure 23: Sequential trimodal in vivo imaging with PET and SPECT probes was achieved through
the above workflow. A. Injection of [18F]-FCP encapsulated [111In]-Labeled Liposomes via tail vein
injection; B. PET imaging, C. SPECT imaging; D. X-ray CT imaging (modified from reference 18).

6.2.7 Cell lines and Culture Conditions
Human cervical carcinoma (KB-3-1) and colorectrectal adenocarcinoma (COLO-205)
cell lines were maintained in humidified incubator at 37 °C and 5% CO2. Briefly, KB-3-1
cells were grown in DMEM/High glucose medium supplemented with 10% fetal bovine
serum (FBS), 5mM L-Glutamine, Penicillin (100U/ml), Streptomycin (100µg/ml) and
Amphotericin B (0.25 ug/ml). COLO-205 cells were cultured in RPMI-1640 medium
supplemented with 10% heat inactivated FBS Penicillin G (100U/ml), Streptomycin
(100µg/ml) and Amphotericin B (0.25 ug/ml). The cells were grown to 70-80%
confluency before using for the experiments.
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6.2.8 Xenograft Animal Model
Female athymic nude mice, (4-6 weeks old, weight: 18-25 g) were purchased from
Harlan Laboratories, USA and provided with food and water ad libitum. Animal
experiments were approved and performed according to the policies and guidelines of the
Animal Care and Use Committee (IACUC) at Virginia Commonwealth University. KB3-1 and COLO 205 cells were cultured as mentioned above and collected for
implantation. Tumor cells (2.5×106/100µL (KB 3-1), 5.0×106/100µL (COLO 205) in
media without serum) were injected subcutaneously into the dorsal region on the right
flank (COLO 205) and left shoulder (KB 3-1) of athymic nude mice. Following
subcutaneous implantation digital caliper measurement of tumor size was accessed, once
the bulge caused by the tumor growth at the injection site was visible, (approximately 5
days). The tumor volume was calculated using the formula 0.523 × (length × width ×
thickness) and assessed thrice per week.

6.3 Results
6.3.1 [111In]-Labeled Liposome Characterization
The mean diameter of PEGylated empty liposome was 168 nm, ζ potential was
-2.3mV. Labeling efficiency of [111In]-Labeled Liposome was greater than 90%.

6.3.2 Biodistribution Studies
6.3.2.1 Biodistribution of 111InCl3
The biodistribution study performed with 111InCl3 showed major accumulation of 111InCl3
in liver (33.10±2.24 %ID/g) and spleen (12.35±1.82 % ID/g) at 6 hours post injection.
The activity was subsequently cleared to (16.24±1.49 %ID/g) and (6.92±0.37% ID/g) at
48 hours in liver and spleen respectively. However, the kidney uptake was increased with
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time (6.86±0.60, 6 hours to 14.54±1.48%ID/g, 48 hrs) suggesting renal clearance of 111In
in later time point. Data representing the biodistribution profile is demonstrated in Table
11 and Fig. 24.
Table 11: Biodistribution of tail-vein injected 111InCl3 (1.07± 0.03) in nude mice (n=3 per time point.
Data are presented as %ID/g (mean±sem) values determined through gamma counting. Tissues were
collected, weighed and gamma emission was measured in a gamma counter to calculate % ID/g
Organs

1hr

6hrs

48hrs

Blood

3.03±0.08

2.12±0.21

0.63±0.13

Heart

1.63±0.11

1.06±0.17

1.48±0.08

Lungs

1.93±0.12

1.93±0.27

2.21±0.01

Liver

17.09±0.21

33.10±2.24

16.24±1.49

Spleen

5.73±0.52

12.35±1.82

6.92±0.37

Stomach

0.27±0.06

0.66±0.18

0.92±0.36

Intestine

0.59±0.04

1.31±0.15

4.03±0.51

Kidneys

4.48±0.67

6.86±0.60

14.54±1.48

Skin

1.01±0.07

1.45±0.16

4.11±0.52

Muscle

0.47±0.08

0.55±0.06

0.86±0.15

Skull

1.05±0.05

1.82±0.25

4.43±2.02

Brain

0.11±0.01

0.11±0.01

0.14±0.00

Femur

0.75±0.12

1.50±0.42

2.04±1.26

- 117 -

Figure 24: Biodistribution of tail-vein injected 111InCl3 (1.07± 0.03) in nude mice (n=3 per time point.
Data are presented as %ID/g (mean±sem) values determined through gamma counting. Tissues were
collected, weighed and gamma emission was measured in a gamma counter to calculate %ID/g

6.3.2.2 Biodistribution of [111In]-DTPA
Table 12 and Fig. 25 show the detailed biodistribution performed in nude mice. The
biodistribution study performed with [111In]-DTPA showed rapid accumulation of [111In]DTPA in kidneys (2.51±1.38 %ID/g) at 1 hour post injection. Rapid clearance from blood
and minimal uptake was observed in other major organs. Major concentration of activity
cleared out within an hour of administration.
Table 12: Biodistribution of tail-vein injected [111In]-DTPA (1.07± 0.03) in nude mice (n=3 per time
point. Data are presented as %ID/g (mean±sem) values determined through gamma counting.
Tissues were collected, weighed and gamma emission was measured in a gamma counter to
calculate % ID/g
Organs

1hr

Blood

0.06±0.02

6hrs
0.00±0.00

48hrs
0.00±0.00
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Heart

0.04±0.01

0.01±0.00

0.00±0.00

Lungs

0.12±0.02

0.03±0.00

0.01±0.00

Liver

0.14±0.06

0.08±0.01

0.02±0.00

Spleen

0.05±0.01

0.03±0.00

0.01±0.00

Stomach

0.04±0.01

0.02±0.01

0.03±0.01

Intestine

0.08±0.03

0.03±0.00

0.01±0.00

Kidneys

2.51±1.38

0.83±0.17

0.28±0.02

Skin

0.24±0.10

0.08±0.01

0.03±0.00

Muscle

0.10±0.06

0.02±0.00

0.00±0.00

Skull

0.14±0.10

0.03±0.00

0.00±0.00

Brain

0.03±0.01

0.00±0.00

0.00±0.00

Femur

0.14±0.06

0.01±0.00

0.00±0.00

Figure 25: Biodistribution of tail-vein injected [111In]-DTPA (1.07± 0.03) in nude mice (n=3 per time
point. Data are presented as %ID/g (mean±sem) values determined through gamma counting.
Tissues were collected, weighed and gamma emission was measured in a gamma counter to
calculate % ID/g
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6.3.2.3 Biodistribution of [111In]-DTPA-DPPE
In Table 13 and Fig. 26, the biodistribution study performed with [111In]-DTPA-DPPE
lipid showed major accumulation of [111In]-DTPA-DPPE in liver (34.11±13.39%ID/g) and
spleen (2.43±0.98% ID/g) at 6 hours post injection. The activity in liver declined to
7.71±0.44%ID/g

in 48 hours. However, the spleen uptake increased in later time point to

(45.11±3.01%ID/g) 48 hours post injection.
Table 13: Biodistribution of tail-vein injected [111In]-DTPA-DPPE (1.07± 0.03) in nude mice (n=3 per
time point. Data are presented as %ID/g (mean±sem) values determined through gamma counting.
Tissues were collected, weighed and gamma emission was measured in a gamma counter to
calculate % ID/g
Organs

1hr

6hrs

48hrs

Blood

17.59±4.53

2.52±0.99

0.15±0.01

Heart

3.78±0.66

1.10±0.42

0.21±0.00

Lungs

5.66±0.77

1.69±0.67

0.34±0.00

Liver

17.30±1.10

34.11±13.39

7.71±0.44

Spleen

2.51±0.31

2.43±0.98

45.11±3.01

Stomach

0.33±0.04

1.17±0.96

0.20±0.05

Intestine

3.58±1.32

1.74±0.44

0.66±0.06

Kidneys

3.95±0.33

1.73±0.79

0.75±0.05

Skin

0.97±0.27

1.31±0.49

0.62±0.08

Muscle

0.94±0.22

0.71±0.23

0.23±0.03

Skull

1.41±0.53

0.46±0.11

0.28±0.04

Brain

0.55±0.05

0.09±0.03

0.01±0.00

Femur

1.08±0.20

0.68±0.37

0.63±0.10
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Figure 26: Biodistribution of tail-vein injected [111In]-DTPA-DPPE (1.07± 0.03) in nude mice (n=3
per time point. Data are presented as %ID/g (mean±sem) values determined through gamma
counting. Tissues were collected, weighed and gamma emission was measured in a gamma counter to
calculate % ID/g

6.3.2.4 Biodistribution of [111In]-Labeled Liposome
The biodistribution study performed with [111In]-Labeled Liposome showed significant
RES uptake. Prominent uptake of [111In]-Labeled Liposome in liver and spleen was
observed, reaching maximum levels at 6 hours of 22.86±3.86, 73.33±12.13%ID/g
respectively which decline gradually to (7.71±0.44%ID/g) and (45.01±2.94% ID/g) in 48
hours. Minimal uptake of [111In]-Labeled Liposome was observed in other major organs.
The detailed biodistribution of [111In]-Labeled Liposome in normal nude mice is
presented in Table 14 and Fig. 27.
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Table 14: Biodistribution of tail-vein injected [111In]-Labeled Liposome (1.07± 0.03) in nude mice
(n=3 per time point. Data are presented as %ID/g (mean±sem) values determined through gamma
counting. Tissues were collected, weighed and gamma emission was measured in a gamma counter to
calculate % ID/g
Organs

1hr

6 hrs

48 hrs

Blood

26.72±8.80

3.74±0.49

0.15±0.01

Heart

5.83±0.73

1.11±0.05

0.21±0.00

Lungs

7.63±1.01

1.97±0.20

0.34±0.00

Liver

15.05±1.07

22.86±3.86

7.71±0.44

Spleen

65.92±4.65

73.33±12.13

45.01±2.94

Stomach

0.70±0.22

0.35±0.07

0.20±0.05

Intestine

2.12±0.68

1.24±0.13

0.66±0.06

Kidneys

4.45±0.35

1.62±0.33

0.75±0.05

Skin

1.39±0.21

0.89±0.18

0.62±0.08

Muscle

0.73±0.21

0.39±0.09

0.23±0.03

Skull

3.35±0.48

0.94±0.21

0.28±0.04

Brain

0.60±0.01

0.13±0.01

0.01±0.00

Femur

1.28±0.10

0.99±0.18

0.6±0.10
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Figure 27: Biodistribution of tail-vein injected [111In]-Labeled Liposome (1.07± 0.03) in nude mice
(n=3 per time point. Data are presented as %ID/g (mean±sem) values determined through gamma
counting. Tissues were collected, weighed and gamma emission was measured in a gamma counter to
calculate % ID/g

6.3.2.5 In vivo SPECT/CT Imaging of [111In]-Labeled Liposome
Radiolabeled liposome (8MBq/200 µL in PBS) was injected intravenously in a female
nude mouse (28.55gms) via tail vein injection. Imaging was carried out using 171 keV
energy gammas 2 hours, 48 hrs and 144 hrs post injection. The resulting images are
depicted below in Fig. 28. The images show that prominent uptake of radiotracer was in
liver and spleen in 2 hours which corresponding to the ex vivo biodistribution data. Later
time points show the subsequent clearance of radioactivity from spleen and liver (Fig. 29).
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Figure 28: In vivo SPECT imaging of normal nude mice injected with [111In]-Labeled Liposome
through tail vein 2, 48 and 144 hrs post injection. The images showed initial uptake of activity in RES
and subsequent clearance with time.
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Figure 29: The clearance profile of [111In]-Labeled Liposome in specific tissues as shown in SPECT
images measured by ROI analysis.

6.3.3 [18F]-FCP encapsulated [111In]-Labeled Liposomes
6.3.3.1 Size Measurement and ζ Potential.
Range of particle sizes was between 40 nm to 1µm with an average size of 221 nm.
Surface charge of liposome formulation was -2.11mV.

6.3.3.2 Entrapment and Labeling Efficiency:

Entrapment efficiency was calculated as the percentage of liposomal encapsulated [18F] FCP. Encapsulation efficiency of [18F]-FCP was 38±2 % (n=3) of the liposomal
formulation. The surface labeling efficiency of liposome with [111In] was greater than
90% after 30 mins at 40º C.
6.3.3.3 Dual Tracer Imaging
In vivo dual tracer imaging was carried out in KB 3-1 (sensitive) and COLO 205
(resistant) tumor xenograft bearing nude mice following a sequential protocol as outlined
in Fig 16 in experimental section. Sensitivity and resistance of tumor was established by
in vitro cytotoxicity assay which was discussed in section 5.3.2. Mice received bolus
injection of after an intravenous injection of [18F]-FCP encapsulated [111In]-Labeled
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Liposomes. There was minimal animal manipulation because of the capability of
automatic moving of bed between different imaging planes in trimodal system which
conserves the full trimodal fusion. Since the dosing comes from the single nanoconstruct,
that conserves the animal position, hence the spatial position was fixed for PET mode and
SPECT mode. PET images acquired one hour post injection using the sequential protocol
was automatically fused to CT. PET/CT image showed the uptake of radioactivity in RES,
mainly liver and spleen. No bleed through of SPECT signal from 111In was visually noted
in the PET images. SPECT images acquired using 171 keV γ’s from

111

In one hour post

injection was automatically fused to CT. SPECT/CT image demonstrated the
accumulation of radioactivity in RES, mainly liver and spleen. This demonstrated the
feasibility of dual tracer PET and SPECT imaging with [18F]-FCP encapsulated [111In]Labeled Liposomes using sequential protocol.
Comparative study performed using [18F]-FCP alone showed the accumulation of activity
in kidneys and bladder (Fig. 30). Activity was also seen in bone marrow, COLO 205
tumor and KB 3-1 tumor. This implies that liposomal encapsulation of [18F]-FCP
changed the pharmacokinetics of the [18F]-FCP by protecting it from systemic clearance
through kidneys.
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Figure 30: In vivo CT and PET/CT image of KB 3-1 (sensitive) and COLO 205 (resistant) tumor
xenograft bearing nude mouse injected with 10 MBq of [ 18F]-FCP through tail vein injection 1 hour
post administration. Image shows the uptake of [ 18F]-FCP in kidneys, bladder and marrow.
KB 3-1(sensitive) has higher uptake than COLO205 (resistant). (A) Coronal Images (B) Volume
Rendered Images

- 127 -

Figure 31: In vivo CT, PET/CT and SPECT/CT images of KB 3-1 (sensitive) and COLO 205
(resistant) tumor xenograft bearing nude mouse injected with 14 MBq of [18F]-FCP encapsulated
[111In]-Labeled Liposome through tail vein injection 1 hour post administration. PET/CT Image
shows the uptake of [18F]-FCP encapsulated in [111In]-Labeled Liposome RES.SPECT/CT image
shows the uptake of [18F]-FCP encapsulated in [111In]-Labeled Liposome in RES. Both image
corresponded to each other in the uptake profile demonstrating the feasibility of dual tracer imaging
from a single nanoconstruct. (A) Coronal Images (B) Volume Rendered Images

6.4

Discussion:

Pegylated liposomal nanoparticles have been used as a vehicle for therapeutic agents. As
a therapeutic agent, liposome should carry adequate load of drug.
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Carboplatin, a cisplatin analog, is an anticancer drug used in clinic for the treatment of
variety of solid tumors. Although carboplatin shows comparable efficacy to cisplatin in
ovarian, bladder and esophageal carcinomas, it has inferior efficacy in germ cell tumors,
head and neck cancer, and lung carcinomas [14]. Carboplatin comprises as a reasonable
alternative to cisplatin in clinic for several treatment regimes. Afforded benefit of
carboplatin over cisplatin is due to its toxicity profile. Carboplatin shows less
nephrotoxicity, neurotoxicity and ototoxicity than cisplatin. However, myelosuppression
is a dose limiting factor for cisplatin.
Resistance to platinum drug remains a huge obstacle in platinum therapy. Carboplatin
resistance arises from reduced concentration of carboplatin reaching the tumor, increased
efflux, intracellular detoxification by glutathione, increased DNA repair, decreased
mismatch repair, defective apoptosis, and impairment in various signaling pathways [15].
Development of new platinum derivatives is prompted with an aim to deliver higher
amount of platinum drugs to tumor and modulate the interaction with the DNA to
overcome the resistance.
We addressed some of those limitations of platinum therapy by synthesizing a novel
carboplatin derivative with non invasive imaging capability. We further extended the
work by developing a radiolabeled liposomal formulation of the novel drug and
investigated its in vivo pharmacokinetics using multimodal imaging. This study
demonstrates the feasibility of optimal radiolabeling the DTPA-derivatized pegylated
liposomes with

111

In. Detailed in vivo biodistribution of [111In]-Labeled Liposome

contrast directly with the behavior of the components of liposome. [111In]-DTPA cleared
very rapidly from the circulation with most activity observed in kidneys suggesting renal
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clearance which agrees to the data published by Harrington et al [6]. Pharmacokinetic
profile of [111In]-Labeled Liposome showed major uptake in RES. Major uptake was
observed in spleen and liver. Gradual accumulation of radioactivity was observed in
spleen with highest uptake (73.33±12.13 % ID/g) in six hours. Minimal accumulation of
radioactivity was observed in other major organs. Subsequent clearance of radioactivity
with time was observed in all organs. Feasibility of SPECT imaging with
[111In]-Labeled Liposome was demonstrated (Fig. 28). Images showed the initial
accumulation of activity in liver and spleen which corresponds to the ex vivo
biodistribution data. Extended imaging with [111In]-Labeled Liposome was enabled
because of the medium half life of

111

In (t1/2= 2.8 days). Images during later time points

(48, 144 hours) showed the gradual clearance of activity from liver and spleen. In vivo
biodistribution studies performed with various components of liposomes enabled
comparative interpretation of [111In]-Labeled Liposome with other components.
[18F]-FCP was encapsulated into [111In]-Labeled Liposome via passive encapsulation
method. Encapsulation efficacy was 38% which was slightly higher than the values
reported in the literature [16, 17]. Surface labeling with 111In was greater than 90% which
agrees to the value reported in literature [13].
Multimodal imaging has been very useful for researchers for a range of in vivo study.
Single modality imaging such as SPECT, PET has been intensively used to gather in vivo
functional data. Complexity of disease state and the unique pathways they express may
not be easily visible for a single modality. Therefore, dual modality imaging further
strengthens the capacity to gather robust data and can image different pathways
simultaneously/sequentially which is otherwise not possible with a single modality.
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Various researchers have presented dual modality imaging with combination of reporters
and tracers. However, there are very few studies that combine two PET and SPECT
radiotracers in a single nanoparticle. Chapman et al [18] demonstrated the dual tracer
imaging feasibility of SPECT and PET probes in living mice using a sequential protocol.
As part of the dosing protocol in the study Chapman et al injected SPECT tracer at first
and acquired the SPECT images and injected the PET tracer after the SPECT scan is
performed. Mastunari et al [19] studied the detection of viable myocardium using dual
isotope simultaneous acquisition SPECT using [18F]-FDG and 99mTc-sestamibi. To our
knowledge, there is no study that performs the dual tracer PET/SPECT imaging from a
radiolabeled drug encapsulated nanoparticle. In this study, we have demonstrated the
feasibility of dual tracer sequential imaging with PET and SPECT using [ 18F]-FCP
encapsulated [111In]-Labeled Liposome (Fig. 31). [18F]-FCP encapsulated [111In]-Labeled
Liposome showed major uptake in RES in both PET and SPECT images. ROI analysis of
SPECT image enabled by

111

In corresponded with PET image enabled by

18

F

demonstrating the feasibility of dual tracer imaging from the single nanoconstruct. From
our previous study with [111In]-Labeled Liposome we observed the uptake of liposome in
RES which is propagated in PET and SPECT images acquired from [18F]-FCP
encapsulated [111In]-Labeled Liposome in an hour after administration. This suggests that
the [18F]-FCP is intact with [111In]-Labeled Liposome. Comparison of PET images
acquired with [18F]-FCP alone (Fig. 30) and PET and SPECT images acquired with [18F]FCP is intact with [111In]-Labeled Liposome showed different pharmacokinetic profiles.
One important finding of this study was [18F]-FCP uptake in KB 3-1 (sensitive) tumor
was higher than COLO205 (resistant) tumor within an hour post intravenous
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administration. The uptake of [18F]-FCP encapsulated [111In]-Labeled Liposome was not
visible in tumors within an hour post intravenous injection. This can be attributed to the
duration needed for the passive accumulation of liposome through EPR effect in tumors.
Liposomal formulation of [18F]-FCP changed the pharmacokinetics of carboplatin
derivative. However, detailed in vivo evaluation using different mouse models and
biodistribution studies is required to confirm the behavior of [18F]-FCP encapsulated
[111In]-Labeled Liposome.

6.5

Conclusion

DTPA-derivatized pegylated liposome was labeled with

111

In. [111In]-Labeled Liposome

was evaluated in vivo with biodistribution and SPECT imaging. [18F]-FCP was
encapsulated in [111In]-Labeled Liposome. Dual tracer feasibility of PET/SPECT imaging
with [18F]-FCP was encapsulated in [111In]-Labeled Liposome was demonstrated.
Different pharmacokinetic profile of [18F]-FCP alone and its liposomal encapsulation in
[111In]-Labeled Liposome was shown in tumor xenograft bearing nude mice.
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CHAPTER 7: CONCLUSION AND FUTURE WORK
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7.1 Summary of Conclusion
Radiolabeled carboplatin derivative [18F]-FCP has been synthesized with

18

F as a

molecular imaging entity for the first time using malonic acid derivative. Manual
synthesis of [18F]-FCP was optimized using low scale of activity. Purification of [ 18F]FCP was optimized using anion exchange method. Automated synthesis of [ 18F]-FCP
using radio synthesizer was optimized using the manual synthetic procedure and inserting
them as macros for sequences. The radiochemical purity was characterized using radioHPLC. Feasibility of in-vivo PET imaging of [18F]-FCP was demonstrated in normal and
KB3-1 and KB8-5 tumor xenograft bearing nude mice. In vivo plasma and urine stability
test confirmed the intact [18F]-FCP after intravenous administration. Detailed
biodistribution in various tissues of [18F]-FCP was performed in normal nude mice.

Radiolabeled Pegylated [111In]-Labeled Liposome has been synthesized as a nanodrug
delivery vehicle. Labeling efficiency was determined. The physiochemical characteristics,
hydrodynamic size and zeta potential, were assessed using DLS. Feasibility of in vivo
SPECT

imaging

with

[111In]-Labeled

Liposome

was

demonstrated.

Detailed

biodistribution of [111In]-labeled Liposome in various tissues was performed in normal
nude mice. Comparative evaluation of tissue distribution of [111In]-labeled Liposome
with

111

InCl3, [111In]-DTPA-DPPE, and [111In]-DTPA was performed to determine the

pharmacokinetic profiles of different components of liposome.

Finally, [18F]-FCP encapsulated [111In]-Labeled Liposome; a dual labeled nanoconstruct,
capable of providing two distinct PET and SPECT signals from a single nanoconstruct
was developed. The physiochemical characteristics including size and zeta potential of
- 136 -

[18F]-FCP encapsulated [111In]-Labeled Liposome were assessed with DLS. Entrapment
efficiency of [18F]-FCP, labeling efficiency of

111

InCl3 were determined. In vivo PET

imaging using [18F]-FCP alone was performed in KB 3-1 and COLO 205 tumor xenograft
bearing nude mice. Feasibility of dual tracer PET/SPECT imaging from a single
nanoconstruct was demonstrated in KB 3-1 and COLO 205 tumor xenograft bearing nude
mice. Comparison of pharmacokinetic profile of naked [18F]-FCP with [18F]-FCP
encapsulated [111In]-Labeled Liposome demonstrated different routes of elimination of
radiotracers.

7.2 Future Work
This is an ongoing work. The demonstration of dual tracer imaging feasibility of [ 18F]FCP encapsulated [111In]-Labeled Liposome establishes the proof of concept of liposomal
formulation of a novel platinum derivative. However, this study did not address the
intensive in vitro characterization of [18F]-FCP encapsulated [111In]-Labeled Liposome.
In vitro characterization such as plasma binding with naked [18F]-FCP, [111In]-Labeled
Liposome and [18F]-FCP encapsulated [111In]-Labeled Liposome needs to be established
to get a detail understanding of the in vivo properties of [18F]-FCP encapsulated [111In]Labeled Liposome. Detail biodistribution studies of [18F]-FCP encapsulated [111In]Labeled Liposome in normal and tumor xenograft bearing mice remains to be
accomplished. Biodistribution study will demonstrate the pharmacokinetic behavior of
[18F]-FCP encapsulated [111In]-Labeled Liposome. The information gathered from this
will help interpret the behavior of the nanoconstruct which can further be compared with
[111In]-Labeled Liposome alone and [18F]-FCP alone. Several factors must be considered
when using a dual tracer probe for an optimal in vivo imaging. Relative properties of each
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radionuclide and its contribution to each modality must be configured before imaging.
Although it is likely that PET detection of [18F]-FCP excludes [111In]-Labeled
Liposome’s 171 keV energy, potential cross talk between [18F]-FCP into the SPECT
acquisition energy window and [111In]-Labeled Liposome into the PET acquisition must
be validated by phantom experiments.
The development of fluorinated carboplatin derivative lends a feasible platform for
developing radiolabeled platinum derivatives with other isotopes. [18F]-FCP enables PET
imaging, a non invasive imaging technology that can be exploited to study the in vivo
pharmacokinetics of drug. Information such as drug distribution, drug ability for blood
brain barrier penetration, bioavailability and tissue concentration and clearance of drug
can be achieved by radiolabeled drug and non invasive imaging.
with a half life of 110 mins. Due to the short half life of

18

18

F is a positron emitter

F, [18F]-FCP enables in vivo

pharmacokinetic studies for a short duration of time. Iodine-124 (124I) is an isotope of
iodine with a half life of 4.18 days. Its modes of decay are: 74.4% EC and 25.6% positron
emission (β+). Feasibility of production of

124

I using a cyclotron offers an advantage

because of the availability of cyclotron on site at VCU. Developing an [ 124I]- labeled
carboplatin derivative using malonic acid derivative will enable in vivo PET imaging and
prolonged in vivo pharmacokinetic study which is otherwise difficult with [18F]-FCP.
Furthermore, encapsulation of [124I]-labeled carboplatin derivative inside [111In]-Labeled
Liposome will enable dual tracer imaging using PET/SPECT. Liposomal formulation will
change the pharmacokinetic profile of the drug and reduces the exposure of naked drug,
hence less normal tissue toxicity and increased bioavailability. The medium half lives of
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both isotopes (2.8 days of

111

In, 4.8 days of

124

I), enable prolonged in vivo study of the

liposomal formulation using non invasive imaging.
In vivo therapeutic merit of

19

F-FCP in comparison of parent compound needs to be

demonstrated. Evaluation of the nephrotoxicity of

19

F-FCP in comparison with its

encapsulated formulation and the parent compound needs to be accomplished.
Modulation of nephrotoxicity by nanoparticle free radical scavengers such as nanoceria
should be investigated.
Developing [18F]-FCP, [124I]-labeled carboplatin derivative using an isotope of platinum,
195m

Pt (half life 4.0 days, energy released from Auger electrons 23keV/decay) would

enable dual therapy, cytotoxic and radiotherapy from the same platinum compound. This
approach of dual therapy from Pt isotope with a molecular imaging entity attached to the
radiopharmaceutical would provide theranostic and synergistic effect in cancer therapy and
provide a platform in optimizing the response of therapy to treatment.
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